Rockbird Media Triumphs with Inaugural Vietnam Edition of the Retail and E-Commerce Summit Asia ACN Newswire

Rockbird Media Triumphs with Inaugural Vietnam Edition of the Retail and E-Commerce Summit Asia

08/30/2024
HO CHI MINH CITY, VIETNAM, Aug 30, 2024 - (ACN Newswire via SeaPRwire.com) - The much-anticipated Retail & E-Commerce Summit Asia (RESA) 2024 made history as it concluded its inaugural event in Vietnam, following its remarkable success across other countries in Southeast Asia. Held on August 22, 2024, at Mai House, Ho Chi Minh City, this landmark summit welcomed retail and e-commerce leaders seeking to capitalize on digital expansion.Attendees, including C-level executives, industry innovators, and emerging entrepreneurs, engaged in a day of transformative discussions and networking opportunities that set the stage for the future of digital retail growth.With the theme "Retail Revolution: Solidifying Growth Through Digital Expansion," the event offered unparalleled insights into the dynamic intersection of retail and technology in burgeoning markets such as Vietnam. Participants gained access to cutting-edge strategies and exclusive content aimed at navigating the complexities of today’s e-commerce landscape, ensuring they were left equipped with actionable knowledge and essential connections.On the valuable insights from the first-ever RESA Vietnam, it’s all about personalization for Le Huynh Phuong Thuc, Managing Director of Guardian Vietnam and one of the event speakers. “The more personalization that we can have, the more we understand about the customer and have the customized offers to the customers at the right timing, with the right value, with the right products.”With Vietnam's market experiencing robust growth, fueled by the potential of digital expansion and increasing foreign investment in retail and e-commerce, RESA offered a prime opportunity to enhance industry knowledge and network. The summit's unique format fostered a collaborative environment where industry leaders could exchange ideas and explore future opportunities.“Given this is the first time that you organized an event here, I say it's impressive,” Huyen Trinh-Thanh, Co-Founder and CGO of Piktina, and another speaker, noted of the event. “I enjoyed the quality of the discussions today. I've got to meet a lot of good people as well as C-suite or C-level people, all of the decision-makers are in the room. The discussions were thoughtful and insightful.”For more information, you can visit: https://rockbirdmedia.comAbout rockbird mediaRockbird media is an international business media company that produces B2B events and offers business solutions.Whether it is through online media and content, must-have business intelligence and analytics, effective networking, and partnering solutions, we help businesses and professionals learn more about the latest trends, and know more about their customers, peers, and competition, to make that decision that allows them to grow.Media contact:annjubelle@rockbirdmedia.com Copyright 2024 ACN Newswire via SeaPRwire.com.
More

持續高額派息的公司，都有什麼不可複製的優勢？

08/30/2024
香港, 2024年8月30日 - (亞太商訊 via SeaPRwire.com) — 2024年，資産荒已成共識，投資者夢寐以求尋找不怕火煉的“真金”。受此影響，具有業績高確定性和高股息的資産價值凸顯。銀河證券策略首席分析師楊超指出，當前，投資者對于現金回報的重視程度日益提升，促使上市公司更積極地采取措施，主動提升分紅頻次與分紅力度。Choice數據顯示，截至8月29日，已有超百家港股上市公司披露中期分紅計劃，包括中國移動（0941.HK）、中國聯通（0762.HK）、九龍倉置業（1997.HK）、中教控股（0839.HK）、李寧（2331.HK）、朝雲集團（6601.HK）等各領域頭部公司。不過，持續高額分紅幷非易事。當前有中期分紅計劃的公司中，“中字頭”港股公司的實力不言而喻，而其他公布派息計劃公司也有一個共同特點，就是構建了有强大核心競爭力的行業優勢。比如九龍倉置業兩個重要商場保持穩定，業績就能穿越地産周期；比如李寧在跑步、籃球和健身三大核心專業品類上保持了科技創新；朝雲集團則以技術創新功效性産品，以履帶式爆品矩陣保持高質量可持續穩利潤發展。由此可見，能長期保持高比例派息的公司，全因其具備同業不可複製的優勢，下面就以朝雲集團為例詳作分析。一、爆品矩陣做“壓艙石”上市公司能够實施持續的高額派息，同行業內保持强競爭力，擁有良好財務狀况和盈利能力的體現。朝雲集團已連續3個半年度業績期營收純利均有雙位數的增長。8月26日發布的財報顯示，2024年H1，公司營收12.49億元（人民幣，下同），同比增長10.3%；純利1.76億元，同比增長29.6%；公司資金儲備充裕，現金、現金等價物及各項銀行存款總額為人民幣26.65億元，中期保持40%的高額派息。“履帶式爆品矩陣”是朝雲集團業績增長的核心驅動力，內在邏輯是公司産品創新能力持續增强。朝雲集團持續進行産品開發和升級，打造了多款强功效性、成分健康、體驗感好、顔值高的大單品，實現産品結構優化幷提升高利潤率産品占比。根據NielsenIQ零售市場數據，朝雲集團的殺蟲驅蚊産品連續十年（2015年－2024年）在中國同類産品中的綜合市場份額排名第一。在新爆品和高複購驅動下，今年上半年，家居護理産品類別收入11.64億元，同比增長11.5%。可以預見，隨著健康與品質生活理念的普及，高品質産品將持續推動朝雲集團業績高質量可持續穩利潤增長。與此同時，公司還憑藉前瞻性市場布局和資源整合能力，從家居護理和個人護理領域向高潜力的寵物護理領域擴張，用强者恒强的邏輯書寫新的篇章。二、“它經濟”的新增長極成了以家清品類作為基本盤且保持穩利潤、可持續發展的朝雲集團，在寵物賽道的布局上也被市場視爲未來增長的重要勢能。而從這份中報看，公司逐漸將這股勢能成功轉化為動能。朝雲集團通過打造人寵互動休閑娛樂的治愈系消費新場所，主打購物中心及生活社區消費業態。公司旗下擁有爪爪喵星球及米樂乖乖寵物生活館兩大實體寵物店品牌，自去年3月開始，展開火速開店模式，截至今年6月30日，已在全國6大城市開設46家門店，遍布深圳、上海、成都、杭州、蘇州、重慶等地。同時，為更符合當下年輕消費群體的審美需求，在集團品牌團隊的支持下，成功完成了寵物門店改造，品牌形象更加突出，更易于被消費者接受，提升了年輕消費群體的覆蓋率。據瞭解，改造後門店收入同比增長233%。中金公司發布研報指出，朝雲集團寵物賽道雙位數擴容可期。公司拓展寵物實體服務業態，成功建立寵物業務護城河。寵物業務與家居清潔、個人護理兩大業務板塊交相輝映，打造了朝雲集團高質量穩增長的多引擎。三、發展潜力兌現，多品牌多品類布局成就全渠道高增長受益于核心業務板塊的成長，朝雲集團實現了新電商渠道高質量穩利潤發展和綫下渠道提質擴容的幷行。今年上半年，綫下實現營收8.43億元，同比增長6.5%；綫上實現營業收入4.06億元，同比增長18.9%。這也說明朝雲集團全渠道發展戰略正在兌現潜力。尤為值得關注的是，公司新電商渠道增勢亮眼。以抖音為例，朝雲集團打造了 “超威驅蚊小綠瓶”等億元單品，長期占據平臺品類各榜單首位，新電商增幅達到300%。未來，以多品牌多品類全渠道的長期增長為方向，朝雲集團有望成為消費品板塊獨特的Alpha。四、業績增速與派息“雙高”，港股投資者的“夢中情司”？綜合上述分析，在消費品板塊衆多公司中，朝雲集團構築起好技術、好産品、好渠道的業務壁壘，形成了同行難以複製的競爭優勢。這一優勢保證了朝雲集團能同時實現高增長、穩利潤和持續高額派息。因此，公司契合了成長投資和價值投資兩種市場風格的特點，完美符合巴菲特曾提出的“成長和價值本是同根生”。我們預計，朝雲集團投資者有望獲得較强的收益確定性。一方面，港股高股息資産長期效益顯著，根據《證券市場周刊》統計，配置港股高股息資産隨著時間的拉長獲得投資回報的概率呈現規律性和顯著性；另一方面，港股市場深度調整後，估值水平已處于歷史相對低位，朝雲集團亦形成“估值窪地”，資産性價比愈發凸顯。可以預見，隨著業績高增長與高派息策略延續，像朝雲集團這樣持續高派息的公司將繼續領跑行業。 Copyright 2024 亞太商訊 via SeaPRwire.com.
More

復星國際未來產業發展和贏利更可預期

08/30/2024
香港, 2024年8月30日 - (亞太商訊 via SeaPRwire.com) — 2024年8月28日，復星國際（HKEX: 0656）公佈2024年中期業績。報告期內，總收入保持增長，達人民幣978.4億元；產業運營利潤保持增長，達人民幣34.7億元，歸母淨利潤為人民幣7.2億元。復星國際董事長郭廣昌在29日上午的業績發佈會上表示，「上半年，儘管宏觀環境充滿挑戰，我們堅定執行聚焦主業戰略，圍繞形成優勢的產業賽道，打造行業數一數二的好公司、好產品，總體來看卓有成效。我們將持續聚焦創新、聚焦全球化，同時注重輕資產運營，以具備競爭優勢的核心能力驅動長遠發展。」今年以來，國內經濟恢復不穩固，國際市場持續波動，讓包括復星在內的中國企業面臨諸多挑戰。復星持續推進戰略聚焦，以核心能力驅動企業發展，實現核心產業提質增效，資產底盤保持穩健。分析人士認為，從復星中期業績報告釋放的信息來看，復星聚焦家庭消費核心產業，先人一步推進創新和全球化，這一戰略持續為復星夯實業務底盤，帶來可預期的穩定贏利；同時，這兩年復星積極推進輕資產運營，優化資產組合，持續降低桿杆，現金儲備充裕，財務安全墊日漸厚實，有望推動市場對復星的價值進行重估。全球化和創新「先人一步」，打造「數一數二」的企業和產品 今年上半年，復星四大核心子公司——復星醫藥、豫園股份、復星葡萄牙保險、復星旅文，總收入達人民幣721.7億元，佔集團總收入的比重達到74%。復星聚焦主業的效果進一步顯現，其在醫藥、旅遊、消費、保險等核心產業賽道的優勢持續提升。在上述核心賽道，通過多年努力，復星已打造出多個在行業排名前列的「數一數二」的企業和產品。例如，復星醫藥位列中國醫藥工業百強第二名，今年上半年也連續第三年入選全球藥企管線規模前二十強；復宏漢霖是首個在港股贏利的中國創新生物製藥公司，旗下多款自主開發的單抗生物類似藥，引領中國生物醫藥行業快速發展，首款重磅產品漢利康是首個獲批上市的國產生物類似藥；復星葡萄牙保險在葡萄牙保險市場市佔率保持第一，在全球葡語區保險市場居前列；智造板塊的翌耀科技是全球領先的自動化和數字化企業。此外在快樂業務板塊，復星旅文旗下Club Med是精緻「一價全包」度假的全球領導者；三亞亞特蘭蒂斯是國內領先的高端綜合度假旅遊目的地，推動海南旅遊進入3.0時代；豫園旗下老廟黃金，是中華老字號，更是享譽全國的珠寶品牌。這些在各自行業「數一數二」的企業和產品，幫助復星持續鞏固在相關產業的領導地位。對復星而言，穩健贏利的增長來自兩個方面，一是創新，一是全球化。在當前國內經濟「內捲」的大環境下，「出海」成為企業界的「必答題」。但復星早在2007年便啟動全球化征程，在海外摸爬滾打17年，今天已成為植根中國的標杆性的全球化企業之一、在全球超過35個國家和地區擁有深度產業佈局。17年出海征程裡，復星捕獲了很多成功的項目，也遇過很多挑戰，最重要的意義在於鍛造了國內企業稀缺的全球化能力，並在全球打通不同市場、不同業態和資源，實現了全球佈局、全球運營和全球發展，全球化深度運營能力持續提升。有一組數據非常能闡釋情況，2024年上半年，集團海外收入達人民幣458.7億元，同比增長4%，佔總收入的比重上升至47%，近半收入來自海外，這在中國企業中並不多見。更重要的是，復星在全球化過程中積極推進旗下企業生態賦能與協同，旗下海內外成員企業在全球化研發、業務拓展、運營及投融資等方面取得多項進展。上半年，復星旗下企業的生物藥出海再獲突破。復星旗下的復宏漢霖，自主開發的漢曲優獲得美國食品藥品監督管理局批准上市，成為在中國、歐盟、美國獲批的「中國籍」單抗生物類似藥；中國首個生物類似藥漢利康獲得秘魯藥監局批准上市，成為繼漢曲優和漢斯狀後，復宏漢霖第三款海外獲批上市的自研藥品。再如復星旅文Club Med地中海俱樂部在全球運營67家度假村，2024年上半年營業額再創新高，達人民幣88.9億元，同比增長10.3%。其中，歐非中東及美洲區持續增長，亞太區復蘇顯著。2024年5月，Club Med 在阿曼簽約中東首個度假村。復星葡萄牙保險，從葡萄牙出發積極拓展海外市場，今年上半年取得葡萄牙境內和國際業務雙增長，海外業績佔比進一步提升，國際業務錄得總保費歐元8.85億元，佔比超過30%；國際業務淨利潤約歐元0.51億元，佔比超過40%。復星旗下全球領先的自動化和數字化企業翌耀科技，也在靜悄悄推進海外拓展，2024年上半年海外新增訂單達到人民幣39.9億元，其中美國市場訂單大幅增加，新增訂單達到人民幣7.5億元，同比增長超過一倍。創新同樣是復星長期積累並始終堅持的核心能力。報告期內，復星持續深化科技與創新能力，創新投入達人民幣35億元；全球視野下的整合式創新模式更加成熟，一批突破性成果正持續為復星帶來穩健贏利，成為復星的增長動力。從創新藥研發方面來看，復星醫藥共有4個產品共9項適應症獲批上市，4個產品共9項適應症進入上市前審批/關鍵臨床階段，9項產品（按適應症計算）獲批開展臨床試驗。復宏漢霖自主研發並生產的創新生物藥不斷取得突破性進展，全球首個一線治療小細胞肺癌的抗PD-1單抗漢斯狀已獲批4項適應症，累計惠及患者超7.5萬，對外授權覆蓋美國、歐洲、東南亞、中東和北非等70多個國家和地區。此外，新一代口服血小板生成素受體激動劑（TPO-RA）蘇可欣新適應症也獲得國家藥監局批准。尖端醫療器械及創新療法的佈局也取得新進展。2024年6月，直觀復星總部產業基地在上海啟用，是直觀醫療在亞太地區最大的研發、生產和培訓一體化基地，達芬奇手術機器人國產化顯著提速。直觀復星Ion支氣管導航操作控制系統也於2024年3月通過國家藥監局批准，並於7月上市。 「輕資產運營」打法成型，價值重估可期得益於業務面的堅實支撐，復星財務面也持續改善。報告期內，復星持續優化資產組合，降低桿杆，財務狀況保持穩健。截至報告期末，集團調整後總債務佔總資本比率為50.2%，維持了2020年以來的下降趨勢；調整後NAV為每股港幣17.4元，顯示當前復星國際股價被嚴重低估。復星也在積極夯實財務安全墊，保持充裕的現金儲備。這次報告期內，復星國際現金、銀行結餘及定期存款達到人民幣1095.5億元，較2023年底增加人民幣約171億元。上市17年來，累計分紅港幣256億元，分紅率逐漸提升，近五年分紅率在20%及以上。就在 2024年6月，國際評級機構標普也充分肯定復星財務戰略成效，確認評級展望為「穩定」。在通過持續的創新和全球化實現穩定贏利的同時，復星面對新的市場環境，也繼續推進「瘦身健體」，陸續退出一些非核心產業，同時積極推進「輕資產運營」，打法也逐漸成型。2024年5月，復星出售德國私人銀行HAL 99.74%股份，引起市場關注，交易完成後，復星將不再持有HAL股份，但全額保留HAFS基金服務業務，以輕資產運營模式，管理約千億歐元資產。在文旅賽道，復星的輕資產運營模式成效顯著，Club Med、三亞亞特蘭蒂斯、太倉阿爾卑斯等IP成為國內旅遊行業標杆。報告期內，Club Med採用租賃及管理模式的度假村佔比為85%，自持度假村佔比降至15%。2024年4月，復星旅文在麗江地中海國際度假區打造的全新IP——阿美澤雪山營地對外開放後，迅速火爆「出圈」，帶動度假區內Club Med麗江度假村與麗江地中海棠岸度假酒店入住率顯著提升。2024年6月，復星旅文還攜手太倉市政府共同打造一站式冰雪主題旅遊度假目的地太倉阿爾卑斯國際度假區二期。該項目總投資超人民幣50億元，由太倉市政府平台出資打造，由復星旅文運營管理。此前復星旅文對阿爾卑斯雪世界的成功運營，為二期項目提供了信心和動力，該項目有望打造多項「世界雪場之最」。與此同時，復星攜手合作夥伴打造了一批產業基金，深度佈局優勢產業。2024年3月，復星醫藥依託在生物醫藥領域的領先優勢，聯手深圳市引導基金等其他七方投資人，共同出資設立人民幣50億元生物醫藥產業基金，募集資金全部投資於生物醫藥、細胞和基因等領域。復星醫藥旗下復健資本通過深圳市公開遴選中標，獨家管理該基金。4月，深圳市政府與復星簽署戰略合作框架協議，雙方集聚優質創新資源，進一步加強在生物醫藥、文體旅遊、時尚消費等領域的合作。也是在2024年4月，復星創富聯合武創投、武漢基金，設立人民幣30億元產業基金，首期規模人民幣11億元。這是湖北省設立人民幣200億元政府引導基金以來，第一隻出資的市場化基金，主要聚焦新一代信息技術、雙碳、智能製造、大消費四大賽道。面對當前的市場環境，可以預計，未來復星仍將積極推進輕資產運營，持續擴大「朋友圈」，加強與各方深度合作，通過優勢互補，實現共贏。多位市場分析人士認為，復星通過創新和全球化的核心戰略，推動業務實現持續穩定盈利，通過退出非核心產業、輕資產運營，持續降債等措施，保持財務面的穩健，有望推動市場對復星的價值重估。郭廣昌認為，未來投資者會更加看重核心產業增長和現金流的穩健，「一次性的資產出售都是短期的，核心業務的成長，才是企業穩健贏利的核心因素」，復星希望打造一個聚焦核心產業的家庭消費產業集團，產業的發展和贏利更可預期。無論是集團層面還是每一塊業務，都要給客戶、投資人提供風險可控、能穩健成長的企業價值。 Copyright 2024 亞太商訊 via SeaPRwire.com.
More

華領醫藥公佈2024年中期業績

08/30/2024
- 全球首創新藥雙功能葡萄糖激酶激活劑（GKA）多格列艾汀（商品名：華堂寧®）于2023年底成功納入《國家基本醫療保險、工傷保險和生育保險藥品目錄》（“國家醫保藥品目錄”）。華領醫藥與商業化合作夥伴拜耳以及80家一級經銷商共同推動多格列艾汀的商業化，開始進入中國31個省級醫藥市場。- 2024年1月1日新版“國家醫保藥品目錄”正式執行，2024年上半年，多格列艾汀的銷售量顯著增加。截至2024年6月30日，共銷售84.6萬盒，實現銷售收入人民幣1.027億元，相比2023年6月30日，同比增長46%。- 得益于政府支持創新藥品的市場准入政策，多格列艾汀加速進入上海、北京和天津等地醫院。截至2024年6月30日，已有2100多家醫院和2900多家藥店開始了多格列艾汀的處方銷售。多格列艾汀在醫院、藥店和網絡藥店銷售的比例分別為72%、20%和8%。- 2024年上半年，公司毛利約為4780萬元，毛利率為46.5%。截至2024年6月30日，公司銀行結餘及現金約13.388億元，相比2023年6月30日，同比增長51.9%。- 多格列艾汀的生産能力繼續擴大，預計2024年産能將達到300萬盒以上，公司已經與合作夥伴建立了更大産能的新工藝，正在接受生産許可部門的監管審查。- 上市後臨床研究加速進行，其中HMM0601研究已入組1368例患者，該研究旨在通過收集2000例2型糖尿病患者1年的臨床安全性數據來評估多格列艾汀的長期安全性。HMM0701研究已入組102例患者，該研究是一項前瞻性真實世界研究，旨在探索多格列艾汀在改善血糖穩態、認知功能和糖尿病緩解方面的臨床獲益。自2022年10月上市銷售以來，過去20個月約有10萬名患者使用多格列艾汀，藥物安全性良好。- 公司與中國香港臨床研究人員合作開展了兩項孟德爾隨機化研究，結果顯示，激活葡萄糖激酶（GK）在降低心血管疾病風險和血脂异常風險方面具有長期獲益性，研究結果已經發表在《心血管糖尿病學》雜志上。公司將携手商業化合作夥伴進一步探索多格列艾汀更加廣泛的臨床適應症。香港, 2024年8月30日 - (亞太商訊 via SeaPRwire.com) — 華領醫藥（“公司”，香港聯交所股份代號：2552）宣布公司及其附屬公司截至2024年6月30日止，6個月（“報告期”）未經審核的綜合業績，以及公司上半年業務進展和未來業務展望。華領醫藥創始人、首席執行官陳力博士表示：“2024年上半年是華領醫藥商業化進程的又一個里程碑。多格列艾汀成功納入國家醫保藥品目錄，大大提升了患者用藥的可及性和可負擔性。在國家和各級政府全鏈條支持生物醫藥産業發展的背景下，在公司與商業化夥伴和生産夥伴的共同努力下，多格列艾汀正迅速提升産能，加速進入全國各地的醫院和藥房，以惠及更多患者。隨著用藥人數的持續增長，多格列艾汀的安全性得到了良好的驗證，其經濟效益和社會效益也大幅提升，為公司未來發展注入了信心。通過銷售擴張和優化運營，我們希望能够在2025年實現公司盈利。目前，華領醫藥還正在全球範圍內開展多格列艾汀的基礎研究和臨床研究，希望不斷拓展多格列艾汀的適應症和適用人群，探索更加廣泛的疾病應用領域，造福不同的患者人群。”臨床研究和公司運營進展摘要- 進入國家醫保藥品目錄後，多格列艾汀速進入醫院和藥店，尤其在上海、北京、天津等城市，政府推出了支持創新藥進入市場的政策。截至2024年上半年，多格列艾汀已經進入全國2100多家醫院。- 上半年，多格列艾汀實現銷售收入人民幣1.027億元，預計在2024年下半年將繼續增長。基于進入醫保建立的新基礎，公司正不斷與合作夥伴密切協作，優化多格列艾汀的生産流程，提高生産效率，從而擴大産能幷降低生産成本。- 公司繼續在約80家醫院開展上市後真實世界研究，增進瞭解多格列艾汀對于2型糖尿病及其幷發症（如記憶力减退、糖尿病腎病）患者的獲益。除此之外，通過與中國香港的臨床研究夥伴的合作，我們使用孟德爾隨機化(MR)研究發現激活GK可以降低心血管疾病和血脂异常風險，有助于公司通過多格列艾汀進一步瞭解GK激活的更多獲益，幷探索多格列艾汀新的適應症。孟德爾隨機化是一種統計方法，利用遺傳變异體來研究暴露（如治療）對結果（如疾病）的因果效應。MR的獨特優勢在于它比傳統的觀察性研究更不容易受到混雜因素和時間相關偏倚的影響，因此在循證醫學中，當隨機對照試驗不可實施時，MR被視為最高循證醫學證據。- 公司正在積極推進針對2型糖尿病患者的上市後真實世界研究，包括在中國內地的HMM0601研究和HMM0701研究，以及在中國香港的HMM0123研究。在這些研究中，公司正不斷積累多格列艾汀單獨用藥，以及多格列艾汀與二甲雙胍、DPP-4抑制劑、SGLT-2抑制劑、GLP-1RA和胰島素等聯合用藥的臨床數據，以優化血糖穩態治療的臨床證據，幷且為多格列艾汀拓展在糖尿病預防和緩解等方面的適應症提供新的證據。- 公司正在持續豐富藥物開發管綫，尤其是固定複方製劑的開發。多格列艾汀-二甲雙胍固定複方劑量已經進入生産工藝驗證階段，公司預計將于2028年推出2型糖尿病治療的新藥。未來，公司將開發更多的多格列艾汀固定複方製劑新藥用于糖尿病及其幷發症，如肥胖、糖尿病腎病等的個性化治療。- 為了進一步發揮多格列艾汀在修復伴有肥胖的糖尿病患者的GLP-1分泌方面的獨特優勢，公司在美國啓動了第二代GKA的1期臨床研究。目前，試驗進展順利，在3組2型糖尿病患者中完成了劑量遞增。公司預計在2024年第四季度發布頂綫數據，以支持未來的藥物開發。- 在2024年美國糖尿病協會（ADA）科學年會上，公司報告了多項基礎研究和臨床研究進展。一項研究顯示，多格列艾汀聯合SGLT-2抑制劑可以改善血糖控制，聯用效果優于兩者單獨用藥，幷且提示多格列艾汀有望在新的適應症中發揮作用，用于與SGLT-2抑制劑恩格列淨等慢性腎病治療藥物聯合用藥，治療中晚期糖尿病腎病患者。- 公司正在使用孟德爾隨機化研究的框架探索多格列艾汀更多的藥物使用機會，如腎病、神經病變相關疾病、眼部相關疾病、認知障礙和癌症等。公司將進一步利用動物研究驗證更多可能的機遇。- 公司將持續優化蛋白變構調節技術，幷積極擴展應用領域，推進負向變構調節劑在GK和GPCR蛋白上的應用。目前葡萄糖激負向變構調節劑已經進入臨床前藥物候選階段，作為先天性高胰島素血症和潜在的血脂异常症的臨床候選藥物。公司將繼續推進mGLUR5 NAM項目在帕金森病（PDLID）、脆性X染色體綜合征(FXS)和藥物成癮中的臨床潜力。財務摘要截至2024年6月30日止，- 公司銀行結餘及現金約13.388億元- 銷售收入約為人民幣1.027億元，共銷售84.6萬盒華堂寧®- 其他收入約為5510萬元，其中拜耳里程碑收益攤銷約4780萬元- 開支總額約2.459億元，其中研發開支約1.198億元前瞻性聲明本文包含有關華領醫藥以及産品未來預期、計劃和前景的陳述。該等前瞻性陳述僅與本文作出該陳述當日的事件或資料有關，可能因未來發展而出現變動。除法律規定外，于作出前瞻性陳述當日之後，無論是否出現新資料、未來事件或其他情况，我們幷無責任更新或公開修改任何前瞻性陳述及預料之外的事件。請仔細閱讀本文幷理解，由于各種風險、不確定性或其他法定要求我們的實際未來業績或表現可能與預期有重大差异。關于華領華領醫藥是一家總部位于中國上海的創新藥物研發和商業化公司，在美國、中國香港設立了公司。華領醫藥專注于未被滿足的醫療需求，為全球患者開發全新療法。華領醫藥彙聚全球醫藥行業高素質人才，融合全球創新技術，依托全球優勢資源，研究開發突破性的技術和産品，引領全球糖尿病醫療創新。公司核心産品華堂寧®（多格列艾汀片）以葡萄糖傳感器葡萄糖激酶為靶點，提升2型糖尿病患者的葡萄糖敏感性，改善患者血糖穩態失調。2022年9月30日，華堂寧®已獲得中國國家藥品監督管理局（NMPA）的上市批准，用于單獨用藥或者與二甲雙胍聯合用藥，治療成人2型糖尿病。對于腎功能不全患者，無需調整劑量，是一款可用于不同程度的腎功能損傷（包括未進行透析的終末期腎損）的2型糖尿病患者的口服降糖藥物。華領醫藥將與領軍企業拜耳共同推動華堂寧®在中國的商業化推廣，以造福糖尿病患者及其家庭。詳情垂詢華領醫藥網址：www.huamedicine.com投資者電郵：ir@huamedicine.com媒體電郵：pr@huamedicine.com新聞免責聲明本材料，如爲上下文論述的準確性和完整性，提及在中國上市的産品相關信息的，特別是標識或要求，應遵循中國監管機構批准的相關文件。另外，相關信息不應被解讀爲對任何藥物或者診療方案的推薦或者宣傳，亦不應替代任何醫療衛生專業人士的醫療建議，涉及醫療的相關事宜務必諮詢醫療衛生專業人士。 Copyright 2024 亞太商訊 via SeaPRwire.com.
More

Hua Medicine Announces 2024 Interim Results

08/30/2024
- Dorzagliatin (trade name: HuaTangNing, world's first dual-acting glucokinase activator (GKA), successfully entered China’s National Reimbursement Drug List for Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance (the “NRDL”) at the end of 2023. Hua Medicine worked with sales promotion partner Bayer Healthcare Company Limited (“Bayer”) and 80 Tier 1 distributors to begin the pharmaceutical market entry in 31 municipalities and provinces in China.- The new NRDL became effective on January 1, 2024. In the first half of 2024, the sales volume of dorzagliatin increased significantly. As of June 30, 2024, sales of HuaTangNing reached 846,000 packs with a sales revenue of RMB102.7 million. The sales revenue increased by 46%, compared with the six months ended June 30, 2023.- Dorzagliatin experienced a fast entry into hospitals, especially in Shanghai, Beijing, Tianjin where the government policies support market entry for novel new drugs. By the end of June 30, 2024, dorzagliatin was prescribed in over 2,100 hospitals and over 2,900 pharmacies. Dorzagliatin was sold principally through hospitals (approximately 72% of total sales), with the remainder of sales through pharmacies (20%) and internet drug stores (8%).- Gross profit in the first half of 2024 is RMB47.8 million, representing a gross profit margin of 46.5%. Bank balances and cash position increased by 51.9% to approximately RMB1,338.8 million for the six months ended June 30, 2024, compared with the six months ended June 30, 2023.- Dorzagliatin manufacturing capacity continues to expand, with the expectation to reach 3 million packs in 2024. New processes for larger capacity have been established with our partners and are under regulatory review for production permit.- Post marketing clinical studies proceeded at an accelerated rate, in which HMM0601 enrolled 1,368 patients and HMM0701 enrolled 102 patients. HMM0601 is designed to evaluate the long-term safety of dorzagliatin by collecting 1-year clinical safety data in 2,000 T2D patients and HMM0701 is a prospective real-world study to explore dorzagliatin’s clinical beneficial effects on the improvement of glucose homeostasis, cognitive function and diabetes remission. A good drug safety profile for dorzagliatin has been observed since its commercial launch in October 2022 – a time span of over 20 months and approximately 100,000 patient exposure.- Two Mendelian randomization studies conducted by our collaborating Hong Kong-based clinical investigators, and published in Cardiovascular Diabetology showed that glucokinase activation can lead to long term benefits in reduction of risks in cardiovascular diseases and dyslipidaemia. New clinical indications shall be further explored with our commercialization partner.HONG KONG, Aug 30, 2024 - (ACN Newswire via SeaPRwire.com) - Hua Medicine (the "Company", HKEx: 2552) today announces the unaudited consolidated results of the Company and its subsidiaries for the six months ended June 30, 2024 (the "Reporting Period"), and the Company’s business progress for the first half of the year and business outlook.Dr. Li Chen, the founder and CEO of Hua Medicine, said, “The first half of 2024 marks a milestone for the commercialization efforts of Hua Medicine. Dorzagliatin's successful inclusion in China’s National Reimbursement Drug List has significantly improved patient accessibility and affordability. Against the backdrop of comprehensive support from the national and local governments for the development of the biopharmaceutical industry, and with the joint efforts of the Company, commercial partners, and production partners, the production capacity of dorzagliatin is rapidly increasing, accelerating its entry into hospitals and pharmacies nationwide to benefit more patients. With the continued growth in the number of users, the safety of dorzagliatin has been well validated, and its economic and social benefits have also greatly increased, instilling confidence in the Company's future development. Through sales expansion and operational optimization, we hope to achieve profitability for the Company by 2025. Currently, Hua Medicine is also conducting basic and clinical research on dorzagliatin globally, aiming to continuously expand its indications and target populations, explore new disease areas, and promote human health and well-being.”Progress of Clinical Research and Company Operations- During the first reporting period under the NRDL, dorzagliatin experienced a fast entry into hospital and pharmacies, especially in Shanghai, Beijing, Tianjin where the government policies support market entry for novel new drugs. The number of hospitals prescribing dorzagliatin exceeded 2,100 in the first half of 2024.- Revenue of dorzagliatin reached RMB102.7 million in the first half of 2024 and is expected to continue to grow in the second half of 2024. As we build off our new foundation under the NRDL, we plan to leverage our well-established partnerships to enhance the dorzagliatin manufacturing process, which is expected to lead to efficiencies, expanded capacity and reduction of cost of goods.- We continued our post marketing clinical studies at approximately 80 hospitals to better understand the benefits dorzagliatin provides to patients with Type 2 diabetes and T2D complications, such as memory loss and diabetes kidney disease. Through our collaboration with our clinical research partners in Hong Kong, we have discovered that glucokinase (GK) activation may bring the benefits of reduction of risks in cardiovascular disease, and dyslipidemia. These results (applying the Mendelian Randomization (MR) methodology) certainly expand our understanding of the benefits of GK activation through dorzagliatin and for uncovering new indications of dorzagliatin in the future. Mendelian Randomization (MR) is a statistical method that uses genetic variants to investigate the causal effects of exposures (e.g., treatments) on outcomes (e.g., diseases). Its unique advantage lies in its reduced susceptibility to confounding and time-related biases compared with observational studies, which is achieved by leveraging the random allocation of genetic variants at conception. In evidence-based medicine, the credibility of evidence from MR is considered to be among the highest, second only to that of randomized controlled trials.- We have advanced our post-marketing real world evidence (RWE) studies HMM0601 and HMM0701 in T2D patients in China, and HMM0123 in Hong Kong, China. In these studies, we are collecting evidence in medical practices for optimization of glucose homeostasis either through dorzagliatin alone or in combination with standard care T2D medications such as metformin, DPP-IV inhibitors, SGLT-2 inhibitors, GLP-1RA and insulin. These results create new evidence for dorzagliatin in the expansion of its indication in diabetes prevention and remission.- We are continuing our drug development pipeline with focus on the fixed dose combination (FDC) of new drug candidates. The new drug Dorzagliatin-Metformin FDC entered manufacturing process validation and our plan is to launch this new medicine for Type 2 diabetes in 2028. Additional new FDC drugs with dorzagliatin will be developed for T2D patients, tailored specifically to address T2D patients with associated complications such as obesity and diabetes kidney disease.- To further leverage the unique advantage of dorzagliatin in restoring GLP-1 secretion in patients with diabetes and obesity, Hua Medicine initiated its Phase I study in the United States with our 2nd generation GKA. The trial has been proceeding smoothly and has already completed dose escalation in three cohorts of T2D patients in the United States. The topline data is expected to be available in the fourth quarter of 2024, supporting future drug development.- At the American Diabetes Association (ADA) Annual Meeting 2024, Hua Medicine reported new scientific data supporting the combination of dorzagliatin with a SGLT-2 inhibitor which led to improvement in glycaemic control. Combination of dorzagliatin with chronic kidney disease (CKD) medicine, such as SGLT-2 inhibitor, empagliflozin, in mid to late stage diabetes kidney disease patients, offers new opportunity to expand dorzagliatin’s indication.- We are exploring more drug repurposing opportunities for dorzagliatin using MR framework, such as renal diseases, neuropathy related diseases, eye related diseases, cognitive disorders, and cancers. Animal studies shall be further performed to validate the promising findings.- We are continuing to optimize our protein allosteric modulation technology (PAMT) and expansion from positive allosteric modulator (PAM), such as GK positive allosteric modulator dorzagliatin, to negative allosteric modulator (NAM) in kinase and G-protein-coupled receptors (GPCR) proteins. The GK NAM program advanced to the pre-clinical candidate (PCC) selection stage and final optimization of the PCC to clinical candidate for congenital hyperinsulinism (CHI), and potentially for dyslipidaemia. We continue to advance mGLUR5 NAM program for its clinical potential in Parkinson’s disease (PDLID), Fragile X syndrome (FXS), and drug addiction.Financial highlightsAs of June 30, 2024,- Bank balances and cash position was approximately RMB1,338.8 million.- Total revenue generated by the Company was approximately RMB102.7 million, reflecting sales of approximately 846,000 packs of HuaTangNing .- Total other income was approximately RMB55.1 million, of which approximately RMB47.8 million was attributable to the amortization of Bayer milestone income.- Total expenditures was approximately RMB245.9 million, of which approximately RMB119.8 million was attributable to research and development expenses.Forward-looking StatementThis article contains the statements regarding the future expectations, plans and prospects for Hua Medicine and the investigational product. The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect as a result of various risks, uncertainties, or other legal requirements.About Hua MedicineHua Medicine is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin on hydrochloride-tolerated T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with varying degrees of renal function impairment (including end-stage renal impairment without dialysis). Hua Medicine partnered with Bayer, a leading global pharmaceutical company, to commercialize HuaTangNing in China, benefiting diabetic patients and their families.For more informationHua MedicineWebsite: www.huamedicine.comInvestorsE-mail: ir@huamedicine.comMediaE-mail: pr@huamedicine.comDisclaimerFor the accuracy and completeness of the context, references to information related to products launched in China, especially label or requirements, should follow the relevant documents approved by the Chinese regulatory authorities.The above information should not be interpreted as a recommendation or promotion of any drug or treatment regimen, nor should it substitute for the medical advice of any healthcare professional. Please consult a healthcare professional for any matters related to medical treatment. Copyright 2024 ACN Newswire via SeaPRwire.com.
More
InfoComm India 2024 to Feature 32 New Exhibitors and close to 30 Launches of Pro AV Technology, Products and Solutions ACN Newswire

InfoComm India 2024 to Feature 32 New Exhibitors and close to 30 Launches of Pro AV Technology, Products and Solutions

08/30/2024
MUMBAI, INDIA, Aug 30, 2024 - (ACN Newswire via SeaPRwire.com) - The countdown is on! InfoComm India 2024, India’s premier professional audiovisual and integrated experience solutions event, opens its doors in just one week. For a decade, the show has delighted the region by showcasing cutting-edge technologies and ideas in all areas of Professional AudioVisual (Pro AV) technologies. The 2024 edition is gearing up for its largest showcase yet – featuring 250 exhibitors and brands, of which over 30 are first-time participants. Visitors can also look forward to experiencing nearly 30 new and first-to-debut products in India and Asia.InfoComm India will take place from 3-5 September at the Jio World Convention Centre (JWCC) in Mumbai, India. Tech innovators, professionals, and enthusiasts are welcome to preview the hundreds of products and solutions ahead of time as well as pre-register to obtain their show badge and also take advantage of the 45 sessions at the InfoComm India Summit 2024 and a host of networking and experiential activities.The tenth edition of India’s Premier Pro AV and Technology showcase expands beyond Pavilions 1 to 3 at JWCC, adding Jasmine Hall (at Level 3) for an even larger showcase of innovative solutions.Some of the featured and first-to-debut in Asia and India include:BENQ: Showcasing India’s No. 1 Google EDLA-certified Board Pro, BENQ presents robust educational tools for an enriched learning experience.CANON: Introducing Canon’s first ‘4K PTZ Remote Camera’ targeting at shooting and distribution of high-quality videos, with quick response in the remote operations, offering flexible operation in video production and broadcasting.AV MASTER TECHNOLOGY: Introducing Super Cue Intelligent PPT Clickers for all kinds of educational sessions or press conferences to deliver flawless presentations with precision control. Over 30 first-time exhibitors will also be demonstrating their innovations alongside established participants, adding vibrancy and dynamism to the showcase. They include:GENERATION AV: Headquartered in Singapore, representing major AV brands such as Optimal Audio, iMAGsystems, Sonance, James Loudspeaker for live events.INFONICS TECHNOLOGIES: India’s own “Leading LED Videowall Manufacturer”.NEOTOUCH: Chennai-based manufacturer, specializing in interactive flat panel with in-built WiFi and Bluetooth connectivity to enhance the productivity at schools and boardroom meetings.InfoComm India 2024 | Jasmine Hall opens earlier at 9.10am on opening day and set to feature even more emerging innovatorsInfoComm India 2024’s new expanded show floor at Jasmine Hall on Level 3 of JWCC will be a hub for networking, learning, and interactive activities. Jasmine Hall opens earlier at 9.10 am to welcome attendees to be part of the Opening Ceremony. Visitors are also invited to join a plethora of networking events within the Jasmine Hall, including:3 and 4 September, 9.30 am – the “Breakfast Networking Hours” hosted by InfoComm India and AVIXA leadership, offers a platform for industry peers to connect and mingle before the show opens.3 September, 5 pm – the “Welcome Networking Event” on opening day provides another opportunity for visitors from diverse sectors and background to build relationships.Visitors seeking a guided experience, and a curated list of products and solutions can sign up for the 3 September, New Tech Products & Solutions show floor tour. Slots are limited!Finally, no visit to InfoComm India 2024 would be complete without checking out the Multisensory Immersive Experience. Co-presented with MSS World + Studio Ocupus, this multisensory showcase at SB01, Jasmine Hall combines cutting-edge projections, interactive floors, and multi-channel surround sound to immerse visitors in the beauty and power of nature.InfoComm India 2024 | A plethora of networking, learning and interactive activities at the show ensures a meaningful and fruitful visit for professional attendees.To skip long queues at the show, register and secure show badge now.For full details on speaker and session lineup, exhibitors, products, registration, and remaining sponsorship opportunities, visit InfoComm India.To access more press information of InfoComm India 2024, please visit: Digital Press Office Kit For more information, please contact:Rest of the WorldAngie EngMarketing DirectorInfoCommAsia Pte Ltdangieeng@infocommasia.comIndiaSooraj DhawanDirectorFalcon Exhibitions Pvt Ltdsooraj@falcon-mail.com Copyright 2024 ACN Newswire via SeaPRwire.com.
More

碧瑤綠色集團公佈2024年中期業績

08/30/2024
香港, 2024年8月29日 - (亞太商訊 via SeaPRwire.com) — 碧瑤綠色集團有限公司（「碧瑤」或「集團」；股份代號：01397.HK）欣然宣佈截至2024年6月30日止六個月（「期內」）之未經審核之中期業績。期內，集團收益約12.9億港元，較去年增加約16.6%，主要由於集團清潔、廢物處理及回收業務持續增長所致。期內溢利約為25.8百萬港元，較去年同期增加約18.5%。整體毛利增加約12.4%至約97.1百萬港元。業務回顧及展望2024年上半年，集團成功獲得共14.8億港元新合約，成功將集團的手頭合約由2023年12月31日約44.3億港元增加約3.8%至約46.0億港元（截至2024年6月30日），為2024年下半年及日後年度，迎來可觀的收益增長。清潔作為集團的核心業務，繼續於期內錄得增長，收益較去年同期增加20.1%至約10.3億港元，佔集團總收益約80.2%。清潔業務毛利增加7.6%，至約66.4百萬港元，主要由於集團與香港特區政府（「政府」）各部門及不同機構的新清潔服務合約所致。集團為政府轄下的街道清潔服務版圖，覆蓋全香港共七區，服務人口約280萬，標誌碧瑤於香港清潔服務市場的領導地位。集團為食物環境衞生署管理政府場地清潔服務版圖，覆蓋全港七區。另外，集團亦為政府多區轄下的街市及康樂場地提供清潔服務，覆蓋全港各大區，其他清潔場地亦遍及各大醫院、政府診所、香港國際機場、學校、屋苑及私人機構等眾多不同場景，顯示集團的專業服務廣受認可。廢物管理及回收方面，期內收益錄得增長，同比增加約7.4%至約1.47億港元，佔集團總收益約11.4%。廢物管理回收業務的毛利增加約60.7%，至約19.2百萬港元，主要由於「塑膠回收先導計劃」進入收成期，以及相關政府合約增加回收點及收入所致。集團期內為政府轄下的五區提供廢物收集服務，服務人口約160萬，亦為香港數千個回收點（包括塑膠、玻璃樽、金屬、廢紙及廚餘），連同公共場所及學校的回收箱，提供收集服務。期內，集團繼續為環境保護署（「環保署」）的「塑膠回收先導計劃」服務合約，為香港多區提供塑膠收集服務。此外，集團亦為香港眾多環保署轄下的「綠在區區」回收環保站、智能回收機及不同機構提供回收服務，負責香港多區的玻璃容器收集及處理，以及廚餘收集服務。綠色科技業務方面，集團結合多項先進的智能數碼科技和物聯網技術，推出了智能回收系統。透過一站式管理及大數據分析平台，即時了解回收機的情況，並可根據回收量，靈活調配運輸，減少物流成本和不必要的碳排放。集團現時為環保署提供智能回收機，以及為私人屋苑提供智能廚餘回收機。目前智能回收機及智能廚餘回收機已遍及香港不同角落，每日24小時為市民提供便捷的回收體驗，並有助提升香港整體回收量。政府現正積極透過回收基金和環境及自然保育基金，向私人屋苑提供全面的財務支援，作安裝廚餘回收機之用。在政府大力宣傳所創造的市場需求下，預計為集團廚餘回收機以及相關智能科技業務，帶來龐大商機。隨著市場對智能回收的需求日漸上升，集團計劃把握智慧城市發展的契機，致力擴大智能回收機及智能廚餘回收機的市場份額。此外，政府積極推展「塑膠飲料容器及紙包飲品盒生產者責任計劃」，計劃今年將條例法案提交立法會審議，預計2025年推出。貫徹「污染者自付」的原則和「環保責任」的理念，相信有助大幅增加塑膠飲料容器及紙包飲品盒的回收率。受益於該計劃，預計將直接拉動碧瑤回收量，為集團多年來於回收服務建設的投資及競爭壁壘，提供吸引回報。期內，集團與怡和機器有限公司合作位於香港屯門環保園的生物炭工廠已試營運，通過熱解技術將園林廢料轉化為高質量生物炭以作各種應用，從而達到「轉廢為材」的目的。香港在綠色和可持續金融的領域緊貼國際趨勢，加速朝着國際綠色金融中心的方向邁進。為配合可持續發展的需求，集團將可持續發展概念注入核心業務和營運範疇，致力為客戶提供一站式及多元化綠色環境服務及可持續採購方案。未來，碧瑤將投放更多資源在人力培訓及綠色採購。同時，集團透過提供廢物審計服務，提供廢物成份數據，協助企業客戶了解產出廢物的可回收量，實現可持續發展的目標。園藝方面，集團為啟德體育園、中西區海濱長廊及屯門震寰路寵物共享公園提供園藝工程。集團園藝服務的客戶廣泛，涵蓋大型私人住宅、政府處所、學校、商場、酒店、機場、香港科學園、香港科技大學及嶺南大學等。蟲害管理方面，集團期內繼續為黃大仙區及大埔區提供蟲害管理服務。此外，集團分別為古物古蹟辦事處轄下29個古蹟及華人廟宇委員會轄下24間廟宇，提供白蟻防治及監測服務。政府正全速發展北部都會區，預計眾多公營房屋陸續落成，其中古洞北以及粉嶺北新發展區的公共屋邨，預計於2026年開始陸續入伙。北部都會區全面發展後，可提供約50萬個新增房屋單位，相信為集團多個核心業務帶來契機。碧瑤主席吳永康先生指：「政府高度重視環境議題，碧瑤主要業務與民生息息相關，屬社會剛性需求，不受經濟環境影響。即使在經濟疲弱下，集團核心業務依然持續增長。儘管期內垃圾徵費暫緩推行，但政府明顯加大力度通過回收商，增加各類回收點，例如加設夜間廚餘回收流動點，方便市民進行回收，不論質和量均有提升，直接拉動集團的回收業務，帶來增長動力。所以，暫緩推行垃圾徵費不單對集團回收業務沒有構成負面影響，反而業務有所增長。長遠而言，減廢回收有助實現政府中「零廢堆填」的目標，有利集團回收及綠色科技業務的發展。」展望未來，集團在致力提高各核心業務的市場份額的同時，積極於香港及以外地區擴張。同時因應集團的發展，適時尋找潛在的併購、合營、或新業務項目，加速未來業務增長，為股東締造可觀及長遠回報。有關集團2024年度中期業績公告詳情，請瀏覽以下網址：http://www.baguio.com.hk/zh-HK/Investor%20Relations/Announcements%20and%20Notices ~ 完 ~碧瑤綠色集團簡介：碧瑤綠色集團（股份代號：01397.HK）成立於 1980 年，為香港最大的綜合環境服務集團之一，提供環衞保潔、資源回收、循環再造、廢物管理、綠色科技、有機肥料及動物飼料生產、園藝綠化工程及害蟲防治等。集團為不同領域的客戶提供服務，包括政府部門、各大機構及跨國企業。集團努力不懈地提升環境、社會及管治(ESG)的表現，以推進集團的可持續發展，以實現將香港推動成為更清潔、更綠色、更健康城市的願景。 Copyright 2024 亞太商訊 via SeaPRwire.com.
More

康希諾生物2024上半年業績亮眼：流腦疫苗引領增長，加快合作與國際化步伐

08/30/2024
香港, 2024年8月29日 - (亞太商訊 via SeaPRwire.com) — 康希諾生物今日披露了2024年上半年業績報告，營收達到3.03億元，其中流腦結合疫苗家族再度展現强勁增長動力，尤其是ACYW135群腦膜炎球菌多糖結合疫苗（CRM197載體）（以下簡稱“MCV4”）曼海欣®作爲亞洲首個腦膜炎球菌四價結合疫苗産品，不僅填補了市場空白，更爲我國嬰幼兒流腦疾病預防樹立了新標杆。康希諾生物兩款流腦疫苗于2024年上半年實現營業收入約2.623億元，較去年同期顯著增長約18%，同時虧損大幅收窄。MCV4不僅在嬰幼兒市場備受矚目，其擴齡臨床試驗也正穩步推進，旨在覆蓋4周歲及以上兒童及成人群體，進一步擴展使用範圍，滿足更廣泛人群的接種需求。同時，康希諾生物緊跟全球研發步伐，與多家國際頂尖研究機構深化合作，不斷推動産品創新和技術突破，幷加速産業化技術轉移和商業化布局。依托新冠疫苗海外商業化的成功經驗，MCV4疫苗的國際市場拓展已蓄勢待發，以東南亞、中東、北非、南美爲主要目標區域，推動注册和商業化工作。此外，國際市場拓展經驗以及與相關方建立的戰略合作關係，也將助力康希諾生物的13價肺炎結合疫苗、組分百白破疫苗組合等産品在海外市場的准入與商業化。同時，公司也在以WHO PQ認證爲方向進行前期準備和籌劃工作，探索國際組織采購産品的可行性；對于全球創新類産品，也會積極探討于發達國家准入的可行性。在營銷策略上，康希諾生物采用了高效精准的商業化模式，依托自主銷售團隊爲核心，結合專業推廣商的力量，迅速將營銷網絡下沉至縣級地區，實現營銷網絡的全面覆蓋。公司堅持以專業學術和客戶需求爲導向，通過深入調研和終端服務，確保産品精准觸達目標群體，同時有效控制銷售費用，實現集約化運營。截至目前，康希諾生物建立了體系完備的商業運營中心以開展國內外的營銷工作，流腦結合疫苗完成了30個省份的准入工作，全面打開了國內市場。流腦結合疫苗的成功商業化也爲即將獲批的13價肺炎結合疫苗打下堅實基礎，目前該産品正在按計劃進行臨床和生産現場檢查。康希諾生物在降本增效方面也取得了顯著成效，銷售費用和管理費用較同期均有下降，分別降低了約13%和39%，顯示出公司運營效率的不斷提升。總體來看，康希諾生物正穩步向集研發、生産、商業化于一體的全能型Biopharma公司邁進。隨著MCV4商業化的成功和13價肺炎結合疫苗等新産品的逐步獲批上市，公司業績有望持續增長。公司管理層對公司前景充滿信心，幷已通過增持公司股份的實際行動表達了堅定支持。 Copyright 2024 亞太商訊 via SeaPRwire.com.
More

CanSinoBIO Reports Outstanding H1 2024 Performance

08/30/2024
HONG KONG, Aug 29, 2024 - (ACN Newswire via SeaPRwire.com) - CanSino Biologics Inc. (CanSinoBIO) today disclosed its performance report for the first half of 2024, with revenue reaching 303 million yuan, while losses were substantially reduced. The meningococcal conjugate vaccines demonstrated robust growth, particularly the Group ACYW135 Meningococcal Conjugate Vaccine (CRM197), known as MCV4 or Menhycia®. As the first quadrivalent meningococcal conjugate vaccine product in Asia, it not only fills the market gap, but also provides a better choice for the prevention of meningococcal disease in Chinese infants and young children. In the first half of 2024, CanSinoBIO's two meningococcal vaccines generated approximately 263 million yuan in revenue, marking a significant increase of around 18% compared to last year.In addition, CanSinoBIO is making strides in clinical trials for expanding the age group of MCV4, aiming to cover children aged four and above, as well as adults. This initiative seeks to broaden vaccination coverage to meet the needs of a wider population. Concurrently, the company is advancing the international market expansion of the MCV4, leveraging its successful overseas commercialization experience with its COVID-19 vaccine. CanSinoBIO is deepening collaborations with leading international research institutions, focusing on registration and commercialization in Southeast Asia, the Middle East, North Africa, and South America. It indicates that the company is accelerating the commercial layout in the global market.Moreover, the market expansion experiences and strategic partnerships will support to expand the reach of its PCV13i [13-valent pneumococcal conjugate vaccine (CRM197, TT Vector)] and DTcP (diphtheria, tetanus and acellular pertussis) components vaccine franchise in global markets. The company is also planning and preparing for WHO PQ certification, exploring the feasibility of international organizations. For global innovative products, CanSinoBIO will actively explore the possibility of accessing developed countries.In terms of commercialization strategy, CanSinoBIO has adopted an efficient and precise model, relying on its direct sales team and leveraging professional promoters to rapidly extend its marketing network to the county-level areas. The company adheres to a professional academic and customer-oriented approach, ensuring that products reach target groups through in-depth research and terminal services. This approach helps control sales expenses and achieves intensive operations. To date, CanSinoBIO has established a well-structured commercial operation center for both domestic and international markets. The MCV4 has been approved in 30 provinces in China, comprehensively opening up the domestic market. The successful commercialization of MCV4 has laid a solid foundation for the upcoming PCV13i, which is currently undergoing clinical and manufacturing site inspections as planned.CanSinoBIO has also made significant progress in cost reduction and efficiency improvement, with sales and administrative expenses decreasing by approximately 13% and 39% compared to the same period last year, respectively, reflecting ongoing improvements in operational efficiency.Overall, CanSinoBIO has integrated R&D, production, and commercialization, gradually transforming into a biopharmaceutical company. With the successful commercialization of MCV4 and the upcoming approval and launch of new products like PCV13i, CanSinoBIO's performance is expected to continue growing. The company’s management team is confident on the company's prospects and has demonstrated strong support through increasing shareholdings. Copyright 2024 ACN Newswire via SeaPRwire.com.
More

Baguio Green Group Announces 2024 Interim Results

08/30/2024
HONG KONG, Aug 29, 2024 - (ACN Newswire via SeaPRwire.com) - Baguio Green Group Limited (‘‘Baguio’’ or the ‘‘Group’’, Stock Code: 01397.HK) is pleased to announce its unaudited interim results for the six months ended 30 June 2024 (the Period”).During the Period, the Group’s revenue amounted to approximately HK$1,291.1 million, representing an increase of approximately 16.6% as compared to the same period last year, mainly due to the continued increase in revenue in the cleaning segment together with the waste management and recycling segment. Profit for the Period amounted to approximately HK$25.8 million, representing an increase of approximately 18.5% as compared to the same period last year. The overall gross profit increased by approximately 12.4% to approximately HK$97.1 million.Business Overview and ProspectsIn the first half of 2024, new contracts awarded to the Group amounted to a total of HK$1.48 billion. As a result, the Group’s contracts on hand reached approximately HK$4.60 billion (as of 30 June 2024), representing an increase of approximately 3.8% from approximately HK$4.43 billion as of 31 December 2023, providing strong revenue growth in the second half of 2024 and subsequent years.The Group’s core business, cleaning services, recorded growth during the Period. Revenue from cleaning services increased by 20.1% to approximately HK$1,034.9 million, accounting for approximately 80.2% of the Group’s total revenue. Gross profit of the cleaning business increased by 7.6% to approximately HK$66.4 million, mainly due to the Group’s new cleaning service contracts with various HKSAR Government (the “Government”) departments and different institutions.The Group’s Government-related street cleaning services cover a total of seven districts, serving a population of approximately 2.8 million, marking Baguio’s leading position in the Hong Kong cleaning services market. The Group’s Government venue cleaning services for the Food and Environmental Hygiene Department cover seven districts in Hong Kong. In addition, the Group also provided Government market related cleaning services and leisure venues cleaning services, covering several districts in Hong Kong, as well as other cleaning sites such as hospitals, Government clinics, Hong Kong International Airport, schools, housing estates and private institutions, demonstrating that the Group’s professional services are widely recognised.Waste management and recycling business recorded growth in revenue during the Period which increased by approximately 7.4% to approximately HK$147.3 million, accounting for approximately 11.4% of the Group’s total revenue. Gross profit of the waste management and recycling business increased by approximately 60.7% to approximately HK$19.2 million, mainly due to the “Plastic Recycling Pilot Scheme” entered the harvest period and the related contracts with the Government increased the recycling spots and revenue. During the Period, the Group provided Government-related waste collection services to five districts, serving a population of approximately 1.6 million, and provided collection services for thousands of recycling spots (including plastic, glass bottles, metals, waste paper and food waste) across Hong Kong, and collection services for recycling bins in public places and schools. During the Period, the Group provided Baguio continued to provide plastic collection services for several districts under the Environment Protection Department (“EPD”) Plastic Recycling Pilot Scheme contract. Baguio also provides collection services for Recycling Stations of “GREEN@COMMUNITY”, introduced by the EPD and smart recycling machines, and other institutions in Hong Kong. In addition, the Group also provides the Government with glass bottles collection and management services and food waste collection services in several districts in Hong Kong.Regarding green technology business, the Group launched a smart recycling system through combination of a number of advanced smart digital technologies and Internet of Things technologies. Through a one-stop management and big data analytics platform, the Group can monitor the real-time situation of the recycling machines, and flexibly deploy transportation according to the amount of recyclables, reducing logistics costs and unnecessary carbon emissions. The Group currently provides smart recycling machines to the EPD and smart food waste recycling machines to private housing estates. At present, smart recycling machines and smart food waste recycling machines are now available in different places of Hong Kong, providing the public with a convenient recycling experience 24 hours a day, and helping to increase the overall recycling volume in Hong Kong. The Government is proactively offering financial aids for private housing estates to install food waste recycling machines through the Recycling Fund and the Environment and Conservation Fund. Under the expected market demand created by the strong advocacy of the Government, it is believed that the Group’s food waste recycling machines and related smart technology business will bring huge business opportunities. With the increasing market demand for smart recycling, the Group plans to seize the opportunity of smart city development, striving to expand the market share of smart recycling machines and smart food waste recycling machines.In addition, the Government is actively promoting the “Producer Responsibility Scheme on Plastic Beverage Containers and Beverage Cartons”, and plans to table the bill to the Legislative Council for scrutiny this year with a view to introducing it in 2025. Enshrining the principle of “Polluter Pays” and the vision of “Eco-responsibility”, the recycling rate of plastic beverage containers and beverage cartons is expected to have a significant increase. The scheme is expected to directly drive the growth of Baguio’s recycling business and create solid returns from our investment in recycling facilities which creates a strong entry barrier to the competition.In partnership with Jardine Engineering Corporation Limited, the Pilot Biochar Production Plant at the EcoPark in Tuen Mun was commenced trial operation during the Period. By converting yard waste into high-quality biochar with pyrolysis technology for various applications, the production plant effectively “turns waste into useful resources”.Hong Kong has made concerted effort to keep pace with international trends in the field of green and sustainable finance, accelerating its progress towards becoming an international green finance hub. To meet the needs of sustainable development, the Group has incorporated sustainability insights into its core businesses and operations and is committed to providing customers with one-stop and diversified green environmental services and sustainable procurement solutions. In the future, Baguio will invest more resources in personnel training and green procurement. Meanwhile, through the provision of waste audit services, the Group provides waste constituent data to help corporate customers understand the amount of generated waste that can be recycled and achieve sustainable development goals.As for the landscaping business, the Group provided landscaping services for the Kai Tak Sports Park, the Central and Western District Promenade and the Inclusive Park for Pets at Tsun Wen Road in Tuen Mun. In addition, the Group provides landscaping services for a wide range of clients, including large private residences, Government premises, schools, shopping malls, hotels, airports, Hong Kong Science Park, Hong Kong University of Science and Technology and Lingnan University, etc.For pest management business, the Group continued to provide pest management services in Wong Tai Sin and Tai Po districts during the Period. In addition, the Group provided termite control and monitoring services to 29 monuments under the Antiquities and Monuments Office and 24 temples under the Chinese Temples Committee respectively.The Government is developing the Northern Metropolis at full speed and a number of public housing estates are scheduled for completion in phases. In particular, intake of tenants at the public housing estates in northern Kwu Tung North and Fanling North New Development Area will commence progressively from 2026. The Northern Metropolis will provide about 500,000 new housing units after fully developed, which is believed to bring opportunities to the Group’s core businesses.Mr. Ng Wing Hong, Chairman of Baguio, commented, “The Government demonstrates a strong commitment to environmental agenda. Baguio’s core businesses are closely related to the livelihood of the general public and are not affected by the economic environment. Despite the presence of economic headwinds, the Group’s core business continues to demonstrate a growth trajectory.While the implementation of the Waste Charging was postponed during the Period, the Government has significantly increased its efforts to increase various types of recycling spots through recyclers. For example, the addition of night mobile food waste recycling spots to facilitate citizens’ recycling, with improvement in terms of quality and quantity, which directly brings growth impetus to the Group’s recycling business. Therefore, the postponement of Waste Charging has no adverse impact on the Group’s recycling business, and on the contrary, results in an increase in business. In the long run, waste reduction and recycling will help achieve the Government’s goal of “Zero Landfill”, and benefit the development of the Group’s recycling and green technology businesses.”Looking forward, the Group will continue to increase the market share of its core businesses and proactively engage in expansion in Hong Kong and beyond. Meanwhile, in line with the development of the Group, it will actively explore potential mergers and acquisitions, joint ventures or new business projects to accelerate future business growth and deliver substantial and long-term returns to shareholders.For details of the Group's 2024 interim results announcement, please visit the following website:http://www.baguio.com.hk/en-US/Investor%20Relations/Announcements%20and%20Notices- End -About Baguio Green GroupEstablished in 1980, Baguio Green Group (Stock code: 01397.HK) is one of Hong Kong’s largest integrated environmental services groups. It provides a full spectrum of professional services including professional cleaning, waste collection & recycling, waste management, green technology, organic fertilizer and animal feed production, horticulture & landscaping, and pest control. It serves a wide range of customers in various sectors including Government departments, statutory organizations and multinational corporations. Fully committed to ESG, the Group works relentlessly to advance sustainable development and create a cleaner, greener, healthier city. Copyright 2024 ACN Newswire via SeaPRwire.com.
More
Anson Resources Underground Injection Control Permit for the Green River Lithium Project Approved ACN Newswire

Anson Resources Underground Injection Control Permit for the Green River Lithium Project Approved

08/30/2024
Anson Resources Achieves Key Permitting MilestoneHighlights:Anson has been granted an Underground Injection Control (UIC) application for Class V wells to dispose of the processed brine at its Green River Lithium Project,The Utah Department of Environmental Quality has granted the application after a public comment consideration,The disposal wells will be located on Blackstone Minerals purchased private property,Application is based on production of 10,000 Li2CO3 tons/annum,Application applies for the development of 4 disposal wells,Conditions for Class V disposal wells include:Brine must be returned to the same Formation it was extracted from, not necessarily from the same horizon as extraction (resulting in no dilution),Volume and geochemistry of disposed brine must be like that of extracted brine,These requirements are met using the Direct Lithium Extraction.NEWPORT BEACH, CA, Aug 30, 2024 - (ACN Newswire via SeaPRwire.com) - Anson Resources Limited (ASX:ASN) (Anson or the Company) through its 100% owned subsidiary Blackstone Mineral NV LLC is pleased to announce that its Underground Injection Control (UIC) application has been approved by the Utah Department of Environmental Quality, Division of Water Quality for its Green River Lithium Project (Project), in the Paradox Basin in south-eastern Utah, USA. The Division of Water Quality has granted the application after its review and consideration of public comments. This UIC application will enable Blackstone to re-inject the spent brine from its Direct Lithium Extraction (DLE) processing plant back into subsurface formations.Anson is planning to drill new disposal wells, at the time of construction of the production plant, for the injection and disposal of the spent brine from its lithium extraction process as part of the development of the project into production. Several historical plugged and abandoned oil and gas wells are in the area and intersected similar brine reservoirs and confirmed the existence of horizons that had been encountered in the Green River area which can be used as the disposal zones. Some of these wells have already been converted into disposal wells which indicates the ability for those horizons to absorb the waste brine.The disposal wells will be located on the private property recently purchased by Blackstone, see ASX Announcement 13 September 2023. When the lithium processing plant has reached its optimal production rate there will be four disposal wells in operation which have been included in the one application, see Figure 1.The spent brine will be pumped via the injection wells into the Paradox Reservoirs, at shallower horizons into the most permeable rock formations reducing the required pumping pressure.Archaeological, environmental and site surveys have been conducted over the proposed areas and these reports have already been submitted to the Utah Division of Oil, Gas and Mining (UDOGM) as part of the drilling application. These surveys, which showed no issues with the already disturbed site, were carried out over the proposed production site, extraction and disposal well locations and surrounding areas. Access to these sites will be via county roads that exit the I70 interstate and already developed roads in existence in the Blackstone property resulting in minimal disturbance.The UIC application was a detailed report and included:Maps of the Area of Review (AOR) - 2-mile radius surrounding the proposed disposal wells,Maps and cross sections of underground sources of drinking water (USDW),Maps and cross sections of local geologic lithology, structures, and hydrologic settings,Injection well construction plan and operational plan,Corrective action plan,Monitoring, recording and reporting plans,Plugging and abandonment,Financial Responsibility (reclamation).Anson's research into the surrounding historic wells has shown that test-work, such as core sampling and flow testing, has been carried out on some of the wells which was suitable for use in providing additional information for the application. Drill Stem Tests were also carried out through some of these intervals which provides information such as porosity and permeability which will assist in the determination of the horizons to be used for disposal.Executive Chairman and CEO Bruce Richardson commented, "This approval from the Government of the State of Utah demonstrates that Anson can continue to progress the project at Green River by following the regulatory process. Progress in the past 12 months at Green River has been much faster than that of the Paradox due to the ownership of the surface area and the support from the local and state government departments and representatives for which we are extremely grateful. The reinjection of the brine back into the geological formation from which it is originally extracted protects other minerals contained in the brine for future use. The Company continues to engage with the local community to ensure that the best options for the development of the project into production are selected. We look forward to an open dialogue with the community and government as the remaining permits are considered as we move closer to production."Positive ESG AspectsThe drill program is designed to have as little impact on the environment, social and recreational activities as possible within the drill location areas which is further increased by carrying out the program on private property. There will be minimal new ground disturbance as the drill pads will be located on flat ground in areas that have already been disturbed.The use of areas where there has already been ground disturbance is consistent with Anson's aim of developing a sustainable project and minimizing environmental impact.Conservation of Water AquifersThe exploration drilling program has been designed to ensure that there is no interaction between the surface waters and the supersaturated lithium brines with the well-being steel cased and cemented in place.The majority of the water-yielding rock units in the area are part of either an upper or lower hydrologic system. The two systems are separated by the impermeable salt beds of the Pennsylvanian Paradox Formation, which underlies the counties in the region (Weir, Maxwell & Zimmerman, 1983) which is further supported by the salinity values intersected in this "surface" drilling recently completed by Anson.Contact Info:William MazeHead of Investor Relationsinvestors@ansonresources.comSOURCE: Anson Resources Copyright 2024 ACN Newswire via SeaPRwire.com.
More
Watch & Clock Fair, Salon de TIME launch in September ACN Newswire

Watch & Clock Fair, Salon de TIME launch in September

08/29/2024
- Kicking off the first round of autumn trade fairs, two watch fairs on 3-7 September will bring in 700+ global exhibitors- Themed “Be on Time”, fairs will showcase different styles of wristwatches, parts, accessories, machinery and equipment- Visitors can gain updates on the latest market information and trends through forums, seminars, watch parades and networking events- Salon de TIME will be fully open to the public for the first time to create a globally renowned annual event for the industryHONG KONG, Aug 29, 2024 - (ACN Newswire via SeaPRwire.com) - Organised by the Hong Kong Trade Development Council (HKTDC), Hong Kong Watch Manufacturers Association Ltd and The Federation of Hong Kong Watch Trades and Industries Ltd, the HKTDC Hong Kong Watch & Clock Fair and Salon de TIME will welcome more than 700 global exhibitors.Themed “Be on Time”, the fairs will feature different styles of wristwatches, parts, accessories, machinery and equipment to provide a one-stop sourcing platform. Under the hybrid EXHIBITION+ model, the physical fairs will run from 3 to 7 September at the Hong Kong Convention and Exhibition Centre (HKCEC), while exhibitors and buyers can meet online through the Click2Match smart business matching platform between 27 August to 14 September.For the first time, Salon de TIME will be fully open to the public for free admission. Sophia Chong, HKTDC Acting Executive Director, said: “This year, the Hong Kong Watch & Clock Fair and Salon de TIME will welcome more than 700 global exhibitors from 15 countries and regions, with new exhibitors from Belgium and Denmark as well as new brands from Greece, Türkiye and the United Kingdom. The two fairs will feature pavilions from Guangdong, Guangzhou, Taiwan as well as South Korea, which is returning after the pandemic, creating globally renowned annual fairs and business opportunities for the industry.”“To explore more new business opportunities, the HKTDC will bring about 80 buying missions from more than 50 countries and regions, including Finland, Germany, Norway, Poland, Russia, Spain, Switzerland, the United Kingdom in Europe; Brazil, Canada and the United States in the Americas; Japan, Singapore, South Korea, Thailand and Vietnam in Asia; and Israel and the United Arab Emirates in the Middle East,” she added.Salon de TIME presents famous global watch brandsSalon de TIME will host more than 130 internationally renowned watch brands and designer collections across five thematic zones: World Brand Piazza, Chic & Trendy, Craft Treasure, Renaissance Moment and Wearable Tech. Some exhibitors will also include retail offerings, allowing them to purchase watches on-site.Numerous styles of watches and accessories to cater to market trends and needsWith sustainability gaining traction in recent years, exhibitors at the two fairs have added a Green Solutions Suppliers label on their products to facilitate sourcing for buyers.Over 20 exhibitors will showcase sustainable watches, including:- German brand Lilienthal Berlin which has launched the world's first watch with a case made of recycled coffee grounds that won the New York Product Design Award, Green Product Award and iF Design Award; - Hong Kong exhibitor Gordon C. & Company Limited, which uses sustainable and biodegradable materials to manufacture watch cases and straps.Wearable tech with smart monitoring technologyThe Paris Olympics has prompted more interest in sport, fitness and wearable tech, providing opportunities for innovative watchmakers. This year’s Wearable Tech zone, led by the Federation of Hong Kong Watch Trades and Industries Ltd and more than 10 companies, will feature a complete industry supply chain, while showcasing software, accessories and the latest technology. Companies taking part include German brand Oskron, which has developed Link2Care, a new wireless monitoring solution for health data, and United Wealth Holdings Limited, which has developed a smart watch incorporating smart movement from Huawei that can also monitor health data.World Brand Piazza – luxury showcase of 10 international watch brandsWorld Brand Piazza, sponsored by Prince Jewellery & Watch for the 14th consecutive year, will present some exceptional luxury watches from 10 international brands: Baume & Mercier, Bovet, Corum, CVSTOS, DeWitt, Franck Muller, Kerbedanz, Montblanc, Parmigiani Fleurier and Sarcar.Watches include Golden Bridge Dragon from Swiss brand Corum. This wristwatch features an 18-carat gold dragon at its core, while the dragon’s eyes, tail and watch body are inlaid with diamonds, pearls and gemstones, respectively. The watch’s 18K gold rectangular movement is composed of more than 190 parts, reflecting its craftsmanship and HK$2.153 million price tag.The showcase also features Swiss brand Bovet’s 7-day Skeleton Tourbillon. The hands on the back side of the dial are reverse-fitted, so they can turn clockwise, using Bovet's proprietary and patented system. This watch is priced at HK$2.136 million.The two fairs will also feature watches and accessories with a range of styles and personalities that can match different market needs:- International Luxury Group returns with 15 international brands, such as Kenneth Cole, Police and Timberland. Among them, the American brand Kenneth Cole launched an automatic movement watch, which uses exquisite screws to embellish the internal structure of the dial and is equipped with a stainless-steel strap. - Hong Kong watchmaking brand ANPASSA features a wristwatch that can be combined with AR technology to present a unique Kowloon Walled City look. - Swiss brand ROMAGO is collaborating with Pokémon to launch a limited edition set of 250 watches. - A limited-edition tourbillon from Hong Kong’s Memorigin uses rare meteorites and a newly developed ultra-thin pearl tourbillon automatic movement to create its Explorer series watch, with a 39mm diameter and a thickness of just 9.9mm.- Swiss classic brand Solvil et Titus presents its Barista Collection of watches with exquisite design and retro style. The barrel-shaped watch body is equipped with an arched glass surface, reflecting the brand's belief that strong emotions brew over time. - Present, a watch and jewellery brand with oriental characteristics, is committed to bringing traditional craftsmanship and culture into the present, with its On the Love of Lotus concept.Unique craftsmanship from European watchmakersSwiss Independent Watchmaking Pavilion (SIWP) and Francéclat are returning this year, presenting 17 international brands. These include:- Pilo & Co Genève, founded by independent Swiss watchmaker Amarildo Pilo. The company has launched Corleone Evoluzione Superleggera, a unique piece with a domed and bevelled sapphire crystal, an ultra-light alloy, a meteorite dial and automatic chronograph movement. - French brand Montignac will present its Marina Capsule series of diving watches, which are made in France and water-resistant to a depth of 200m. The watch body is equipped with a unidirectional bezel and luminous coating, which can track diving time and depth.Nine major zones for buyersThe Watch & Clock Fair is made up of nine zones. The Pageant of Eternity zone showcases high-end OEM and ODM watches, while other zones cover complete watches, pre-owned watches, clocks, machinery and equipment, OEM smart watches, packaging & display, parts and components and trade services.Forums and seminars explore industry trendsVisitors can also gain first-hand market information and updates on the latest industry trends through forums, seminars, watch parades and networking events.At the Hong Kong International Watch Forum on 3 September, global watch association representatives will provide an overview of global trade and industry trends with their insights and visions on reshaping the global watch industry towards sustainability.At the Asian Watch Conference on 4 September, global market research agency Euromonitor International (Hong Kong) will analyse the latest market developments around this year’s theme, “The Infinite Possibilities with Watches”. Mr Frank Chen, Sales Director of Module of Huawei Device BG, and Mr Pierre Burgun, CEO of Pierre Lannier, will discuss the prospects of health monitoring and innovative practices for wearable tech as well as the latest trends for stylish wristwatches.On 5 September, Dr James Chung-Wai Cheung, Research Assistant Professor and Member of Research Institute for Smart Ageing of The Hong Kong Polytechnic University, and Mr Michael Ertl, CEO and Founder of ME & Friends AG, and Mr Paul Anthony Yuen, Secretary General of The Federation of Hong Kong Watch Trades & Industries Ltd., will explore how age-forward technology can empower the ageing population to maintain independence and embrace a more connected, active lifestyle.In addition, the HKTDC, The Federation of Hong Kong Watch Trades & Industries Ltd and the Hong Kong Watch Manufacturers Association Ltd are jointly organising the 41st HK Watch & Clock Design Competition to cultivate a new generation of watch designers and technicians and to promote innovation and continued development in watch design.The competition has two categories – Go Beyond Innovation for the Open Group and Talent Moment for the Student Group. The Made-to-Sell Award is also newly added to recognise student entries with market potential. Artist Benjamin Yuen has been invited as a guest judge this year.Award-winning works and finalists will be exhibited during the fairs, while the award ceremony will be held on 7 September at The Dial in Hall 3FG of Salon de TIME.A variety of events, lucky draws and workshop for the publicAt Salon de TIME, Mr Carlos Koo, Founder of CK Engraving and Metal Engraving Artist, will demonstrate the art of watch engraving. Watch influencers Billy Chan and Ko Sir will reveal their views into generational mindsets and offer insights on investing in luxury timepieces respectively.Mr Gary Ching, Founder of ANPASSA, will host a workshop titled “Watchmaking 101 Craft Your Own Timepiece”. A series of product launches and watch parades will be featured with celebrities, including table tennis players Doo Hoi-kem and Wong Chun-ting who just represented Hong Kong in the Paris Olympics, Hong Kong singer Aka Chio, YouTuber Jeffrey Fok and more.Visitors can also participate in lucky draws and join Smart Bidding to bid on their desired watches starting at a 90% discount off the retail price.In addition, Asia’s premier fashion event CENTRESTAGE will be held from 4 to 7 September at the HKCEC, showcasing designer brands from around the world. Visitors can view the latest products from more than 380 watch and fashion brands at the same venue.Export performance, Hong Kong watches and clocks:Q2, 2024Q1, 2024Change per quarter41.334.3+7Retail sales, Hong Kong watches and clocks*:20232022Change per yearHK$32.5 billionHK$25.6 billion+27%*Data from EuromonitorPhoto download: https://bit.ly/3MoUWCZThe HKTDC Hong Kong Watch & Clock Fair and Salon de TIME take place on 3-7 September at the Hong Kong Convention and Exhibition Centre. Introducing fair highlights at a press conference are Sophia Chong, HKTDC Acting Executive Director (4th from left), Eric Lai (3rd from left) and Edmond Ng (4th from right), Co-Chairmen, HKTDC Hong Kong Watch & Clock Fair Organising Committee 2024. Hong Kong exhibitor Gordon C. & Company Limited uses sustainable and biodegradable materials to manufacture watch cases and straps. German brand Oskron has developed Link2Care, a new wireless monitoring solution for health data. Sponsored by Prince Jewellery & Watch for the 14th consecutive year, World Brand Piazza presents rare watches from 10 international brands, including Corum’s Golden Bridge Dragon and BOVET’s 7-day Skeleton Tourbillon.Swiss classic brand Solvil et Titus presents its Barista Collection of watches with exquisite design and retro style. The barrel-shaped watch body is equipped with an arched glass surface, reflecting the brand's belief that strong emotions brew over time.Hong Kong watchmaking brand ANPASSA features a wristwatch that can be combined with AR technology to present a unique Kowloon Walled City look.Swiss brand ROMAGO collaborates with Pokémon to launch a limited edition set of 250 watches.Pilo & Co Genève, founded by independent Swiss watchmaker Amarildo Pilo, has launched Corleone Evoluzione Superleggera, a unique piece with a domed and bevelled sapphire crystal, an ultra-light alloy, a meteorite dial and automatic chronograph movement. The 41st HK Watch & Clock Design Competition has two categories – Go Beyond Innovation for the Open Group and Talent Moment for the Student Group. Award-winning works and finalists will be exhibited during the fairs.Dancers at the press conference showcase 27 selected timepieces. Websites:Hong Kong Watch & Clock Fair: https://www.hktdc.com/event/hkwatchfair/enSalon de TIME: https://www.hktdc.com/event/te/enMedia enquiriesPlease contact the HKTDC’s Communications & Public Affairs Department: Johnny TsuiTel: (852) 2584 4395Email : johnny.cy.tsui@hktdc.orgBubble MaTel: (852) 2584 4369Email : bubble.ma@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2024 ACN Newswire via SeaPRwire.com.
More
域塔物流科技控股有限公司成功於美國納斯達克上市 ACN Newswire

域塔物流科技控股有限公司成功於美國納斯達克上市

08/29/2024
香港, 2024年8月29日 - (亞太商訊 via SeaPRwire.com) — 域塔物流科技控股有限公司（「域塔物流科技」）（納斯達克代碼：RITR）已於2024年8月23日正式在納斯達克交易所上市，這不僅是集團邁向國際化市場的重要里程碑，集團將致力於推動智慧物流生態圈的建設，為行業注入新動能。域塔物流科技成立於2015年，通過整合房地產、物流運營和創新科技，提供全面的物流解決方案，主要業務包括以下兩大部分：1. 資產管理和諮詢服務 – 搜尋和開發物流地產，通過科技賦能資產價值，並與合適的物流運營商建立聯繫。2. 建設管理和工程設計 - 為物流地產開發提供專業的項目管理服務。域塔物流科技的一站式營運模式能夠深入了解客戶需求，提供量身定制的解決方案，有效降低運營成本，並優化整體物流運營。作為香港PLT（房地產+物流科技）領域的先驅，域塔物流科技擁有20多年的行業經驗，與業界持份者擁有深厚關係。域塔物流科技為物流運營商（第三方物流公司）和投資物流房地產項目的資本合作夥伴提供服務，幫助第三方物流公司獲得物業、許可證和戰略規劃；還會協助資本夥伴搜尋、開發和管理物流資產，發揮其資產最大價值。域塔物流科技的綜合解決方案和資深的行業知識，成為香港物流服務市場中的關鍵競爭優勢。域塔物流科技在首次公開募股（IPO）中，所募集的資金將用於加速產品研發、擴展全球業務版圖，以及持續優化服務品質。未來，集團將致力於鞏固在智慧物流領域的領導地位，攜手全球合作夥伴，共同推動供應鏈的數位化轉型，引領智慧物流步向新的發展紀元，為客戶創造更卓越的價值。 Copyright 2024 亞太商訊 via SeaPRwire.com.
More
Reitar Logtech Holdings Limited (RITR) Successfully Listed on Nasdaq ACN Newswire

Reitar Logtech Holdings Limited (RITR) Successfully Listed on Nasdaq

08/29/2024
HONG KONG, Aug 29, 2024 - (ACN Newswire via SeaPRwire.com) - Reitar Logtech Holdings Limited ("Reitar Logtech") (NASDAQ: RITR) has officially listed on the Nasdaq stock market on August 23, 2024. This marks an important milestone in the company's internationalization, also signifies Reitar Logtech's commitment to driving the formation of smart logistics ecosystem, injecting new momentum into the industry.Founded in 2015, Reitar Logtech provides end-to-end logistics solutions by integrating real estate, logistics operations, and innovative technologies through two main segments:1. Asset management and consulting services - They source and develop logistics properties, enhance asset value through technology, and connect with suitable logistics operators.2. Construction management and engineering design - They provide project management services for logistics property development.Reitar Logtech's one-stop model allows them to deeply understand customer needs, provide tailored solutions, lower operating costs, and optimize overall logistics operations. As a pioneer in the PLT (property + logistics technology) space in Hong Kong with over 20 years of industry expertise and strong relationships with key players.The company serves both logistics operators (3PLs) and capital partners investing in logistics real estate projects. Reitar Logtech help 3PLs with property procurement, licensing, and strategic planning. The company help capital partners to source, develop, and manage logistics assets to maximize value. Reitar Logtech's integrated approach and deep industry knowledge are their key competitive advantages in the concentrated Hong Kong logistics services market.Reitar Logtech raised funds through its initial public offering (IPO) to accelerate product R&D, expand its global business footprint, and continuously optimize service quality. Going forward, Reitar Logtech will strive to consolidate its leadership position in the smart logistics field, partnering with global partners to drive the digital transformation of the supply chain, and lead the smart logistics industry into a new era of development, creating greater value for customers. Copyright 2024 ACN Newswire via SeaPRwire.com.
More

Noah Holdings Announces $50M Share Repurchase, Signaling Confidence in Overseas Growth

08/29/2024
HONG KONG, Aug 29, 2024 - (ACN Newswire via SeaPRwire.com) - Noah Holdings Limited ("Noah" or the "Company") (NYSE: NOAH and HKEX: 6686), a leading and pioneer wealth management service provider offering comprehensive one-stop advisory services on global investment and asset allocation primarily for Mandarin-speaking high-net-worth investors, today announced its unaudited financial results for the second quarter of 2024.Noah recorded total net revenue of RMB 616 million in the second quarter of 2024. The wealth management business generated net revenues of RMB 416 million, while the asset management business reported net revenues of RMB 192 million.Strategically Overseas Expansion and Comprehensive investment SolutionsNoah’s overseas expansion is gaining momentum as client demand for global asset allocation strengthens, with overseas net revenue contribution increasing to 46.3% in the first half of 2024 and asset under management increasing 14.1% year-over-year during the quarter. Noah also raised US$ 338 million for overseas private equity, private credit, and other primary market funds year-to-date, a significant 40.2% year-over-year increase.Income from operations was RMB 134 million, an increase of 10.3% sequentially, with an operating margin of 21.8%, an increase from 18.7% in the first quarter of 2024. These results directly reflect the early success of Noah’s strategic transformation as it implements effective cost control measures, restructures its domestic business, and accelerates its expansion overseas."The pace of our overseas expansion is gaining momentum," said Zhe Yin, the Chief Executive Officer of Noah Holdings. "Our team of overseas relationship managers directly supporting this expansion grew 101.8% year-over-year and 24.2% sequentially during the quarter. While we are still in the relatively early stages of our overseas expansion, these results reflect the direction we are headed in going forward.”“Domestically, we are focused on stabilizing operations by streamlining our branch network to reduce overhead costs and adjusting our client service model to comply with evolving regulatory requirements by separating relationship and business development managers into different independent business units. While these initiatives may temporarily impact business activity over the next few quarters, they will ensure our ability to effectively and compliantly serve clients with a comprehensive portfolio of products in the long term. I am pleased with the progress we have made this quarter in expanding overseas, and confident in both our long-term growth potential and ability to consistently generate returns for shareholders."As of June 30, 2024, the number of overseas registered clients increased by 6.7% sequentially 23.0% year-over-year to 16,786, further reflecting the growing demand for overseas asset allocation. Notably, the number of overseas diamond and black card clients saw an even more substantial year-on-year increase of 14.2%.The Company also observed a shift in product preferences, a trend that aligns with the forward-looking strategies outlined in Noah's Chief Investment Office’s (CIO) house view. Interest in investment products increased substantially as a result of expectations for a potential Federal Reserve rate cut during the second half of the year. Known for its expertise and ability to offer clients alternative investments on a global basis, Noah is uniquely positioned to capitalize on this opportunity to grow its USD AUA.As of June 30, 2024, Noah’s overseas relationship manager team grew to 113, a 24.2% increase sequentially. This expansion reflects Noah’s commitment to building a robust presence in key international financial hubs, and enhances its ability to serve high-net-worth clients with comprehensive global investment solutions.Prioritizing Shareholder Interests and Delivering Sustained ReturnsAs part of its commitment to enhancing shareholder returns, the board of directors of the company authorized a share repurchase program under which the Company may repurchase up to US$50 million of its American depositary shares or ordinary shares, effective immediately. The authorized term for carrying out this share repurchase program is two years.Noah announced in November 2023 that a new capital management and shareholder return policy (the “Policy”) had been adopted, pursuant to which up to 50% the Company's non-GAAP net income attributable to shareholders of the preceding financial year will be allocated to a Corporate Actions Budget which will serve various purposes, including dividend distribution and share repurchases. The share repurchase program announced on August 29 2024 does not form a part of the Corporate Actions Budget under the Policy. The Corporate Actions Budget based on Noah’s financial performance in 2024 is expected to be determined and announced alongside the Company’s earnings results for the fourth quarter and full year ending on December 31, 2024.Ms. Jingbo Wang, co-founder and chairwoman of Noah, commented, “This share repurchase program, along with the dividend payout we just completed, reflects our unwavering commitment to prioritizing shareholder interests and delivering sustained returns. While China’s wealth management industry is navigating a challenging period and undergoing a transition, we remain confident in Noah’s unique advantages stemming from our deep understanding of Mandarin-speaking high-net-worth individuals’ (HNWI) needs and our ability to deliver products and services to this still-growing client base. We are one of a few independent firms that maintains access, through years of investor education, to a large group of qualified individual investors who continue to seek professional services.”“As such, we believe that our stock is deeply undervalued and does not reflect our growth prospects, robust balance sheet and cash reserves, or the special bond we have formed with the Mandarin-speaking HNWIs globally. We value both our long-term and new shareholders and are committed to sharing our success with them through more proactive capital allocation policies moving forward.”Strengthening Commitment to ESG PrinciplesIn the first half of 2024, Noah published its 10th Annual environmental, social, and governance (ESG) report, highlighting its decade-long commitment to corporate responsibility and sustainable practices. Additionally, Gopher Asset Management, Noah's asset management arm, also joined the latest Nature Responsible Management initiative, Spring, announced by Principles for Responsible Investment (PRI) in 2024, reinforcing its role in driving responsible investment practices in order to halt and reverse biodiversity loss by 2030.By aligning with the PRI, Noah reaffirms its commitment to integrating ESG factors into its investment processes, fostering sustainable and responsible investment practices that benefit all stakeholders.Noah continues to adapt and evolve amidst a challenging market environment. The Company’s strategic initiatives, focused on global expansion, technological innovation, and sustainable practices, are beginning to yield tangible results, laying a strong foundation for continued success in the years to come. Copyright 2024 ACN Newswire via SeaPRwire.com.
More

光大環境深耕技術研發，加快培育新質生產力

08/29/2024
香港, 2024年8月29日 - (亞太商訊 via SeaPRwire.com) — 日前，中國環保行業龍頭中國光大環境（集團）有限公司（257.HK）（下稱「光大環境」或「公司」）公佈的2024年度中期業績顯示：2024年上半年，公司實施創新驅動發展戰略，推動科技創新「拆門破牆」，管理數字化進程加速，科技成果轉化持續發力，持續打造開放共享科技創新生態，為培育發展新質生產力奠定基礎。科技成果轉化應用取得新突破光大環境積極探索業務新賽道，聚焦新業務和新技術的培育，以技術研發賦能各業務發展並取得實效。在垃圾發電、污泥處理、污水處理等關鍵技術領域，公司研發團隊持續攻克技術難題，有效提升了處理效率，節省運營成本，提升經濟效益。2024上半年，光大環境實現科技研發成果轉化13項，涵蓋高效濕法脫硫技術、脫硫脫硝一體化技術、厭氧氨氧化技術、倒極電滲析(EDR)技術、自動燃燒控制(ACC)技術、乾式厭氧等領域。其中，公司推進無人打焦機服務進入市場化運營階段，完成內外部打焦服務二十餘次，還將厭氧膜生物反應器（MBR）、智慧化等技術工藝應用於公司旗下項目，促進了項目運營質效雙升，取得了良好的經濟效益和社會效益。針對生產工作中的痛點難點，公司推動飛灰資源化利用、煙氣淨化、污水處理廠全流程智能精準控制系統等重大課題的研發和試點。公司旗下環保水務持續開展「五小創新」工作，依託運營管理和工程建設過程中的小發明、小改造、小革新、小設計、小建議，更好實現項目的控本增效。技術與裝備創新邁上新台階光大環境高度重視技術研發和裝備製造，圍繞「智造賦能戰略實施主體」戰略定位，積極構建「光大智造」發展新格局，加快裝備製造轉型升級。2024年上半年，光大環境多項裝備製造課題的成果轉化有序推進。其中主要成果包括：推動沼氣高值化利用、飛灰資源化、生物質製醇技術等領域的探索；「200噸／日快裝式小型固廢處置成套裝備研發及產業化」攻關項目通過驗收，促進裝備產品迭代升級；推出的75噸╱日小型爐成套設備已於四川馬爾康承接的環保項目進入安裝調試階段；成功落地廢舊電池資源化示範項目，該項目也成為了江蘇省首個電池回收與再利用示範項目。管理數字化轉型步伐穩步加快光大環境堅定推進科創產品市場化，以數字化、信息化建設助力控本增效，持續優化科創體制機制。其中，公司重點推動業務財務一體化、推動智慧管理平台建設，強化財務、資金、檔案等管理平台的數字化建設，加強系統內數據協同與融合，有效提高管理效率。公司還積極推進「裝備雲服」智慧維保平台建設，不斷拓展環保設備全生命週期數字化服務，為客戶提供更加優質、高效的服務。 Copyright 2024 亞太商訊 via SeaPRwire.com.
More

秉持戰略定力，堅守價值成長，造就優質標的-陽光保險

08/29/2024
香港, 2024年8月29日 - (亞太商訊 via SeaPRwire.com) — 2024年上半年，保險業高質量轉型步入深水區，量升質增態勢愈發明顯。目前行業估值和持倉仍處底部，β屬性與政策多重利好將有助整個板塊估值修復，仍具長期配置價值。上市險企中，陽光保險（6963.HK）於近日披露中期業績，無論是總保費收入還是盈利能力，均呈穩健提升之勢。據悉，2023年陽光保險集團董事長張維功提出全面佈局打造「科技陽光、價值陽光、知心陽光」的新陽光戰略，按照「一張藍圖繪徹底，看著藍圖幹到底」的戰略定力，全面實現公司的戰略升級。2024年上半年，在持續推進「新陽光戰略」驅動下，公司保險主業核心能力進一步穩固加強，整體市場競爭力有效提高，經營業績穩步增長。根據業績公告，2024年上半年，公司實現總收入424.49億元（人民幣，下同），同比增長8.9%。保險服務收入314.9億元，同比增長4.4%。歸屬於母公司股東的淨利潤31.4億元，同比增長8.6%。內含價值為1,126.4億元，較上年末增長8.2%。經營業績與價值創造能力雙重提升高質量發展與高價值成長，是陽光保險始終堅持的發展方向，意味著既要持續推動經營業績穩步向好，也要深入落地「價值陽光」戰略，不斷增強價值創造能力。從主業發展來看，2024年上半年，壽險業務保持較快發展，壽險總保費收入517.6億元，同比增長12.9%；上半年新業務價值37.5億元，同比增長39.9%。財險業務規模穩健增長，原保險保費收入246.5億元，同比增長12.4%。車險原保險保費收入132.9億元，同比增長3.2%，承保綜合成本率99.7%，實現承保盈利；非車險原保險保費收入113.6億元，同比增長25.5%，其中農險業務同比增長38.3%，健康險業務同比增長48.5%；承保綜合成本率98.5%，實現承保利潤1.6億元。從價值創造來看，2024年上半年，壽險多元渠道協同發展，其中個險價值快速增長，隊伍企穩回升、產能持續提升。財險業務品質保持良好，非車險保費佔比46.1%，同比提升4.8個百分點；家用車保費在車險中佔比62.4%，同比提升1.5個百分點，業務結構持續優化。客戶經營有聲有色，優質服務彰顯「溫度」踐行「客戶思想驅動」理念，是陽光保險紮實落地「知心陽光」戰略的重要落腳點。尤其隨著消費者需求日益多元化、差異化，客戶經營這一保險行業一直以來的重點課題，已經成為公司能力體系建設的核心之一，也是2024年上半年的重頭戲。陽光人壽強化客戶思想，以「三╱五╱七」產品體系為抓手，持續推進「縱橫計劃」，不斷豐富「三╱五╱七」產品體系內涵，落地差異化增值服務，持續滿足客戶不同生命週期的保險需求。據悉，「三╱五╱七」產品體系即對於「人的一生需要幾張保單」這一社會性難題給出了一個簡單清晰、通俗易懂的客戶保單需求概念結論——「三張保單保一生、五張保單全家福、七彩陽光滿堂紅」，並相應打造了豐富的產品服務體系，使陽光成為行業第一家以全客戶視角、將客戶壽險保單需求清晰而通俗易懂地向社會作出闡釋的公司。陽光財險持續深化客戶需求洞察研究，致力於建立便捷的客戶服務體系，積極提供溫暖貼心、專業可信的服務產品，品牌口碑再上一層樓。個人客戶方面，上半年家用車續保率64.2%，同比持續提升，個人車險客戶非車險產品購買比例達到55.5%，同比提升7.6個百分點。團體客戶方面，持續推進「夥伴行動」風險管理服務落地，2024年上半年，累計為8,595個企業客戶提供科技減損和專業風險諮詢服務，升級打造「保險+科技+服務」的全量風險管理服務模式。在上半年保險行業延續深度轉型的背景下，陽光保險憑藉創業初心與不變的戰略定力堅毅前行，不斷提高自身綜合競爭力，取得優異的成績，頗為難得。作爲本世紀成立的205家內地保險企業中唯一上市的傳統保險企業，預期公司將在穩固基本面的支撑下，實現估值重塑，尤其在被納入恒生綜合指數後，未來流動性將持續增大，作為優質標的對海內外的「聰明投資者」將更具吸引力。 Copyright 2024 亞太商訊 via SeaPRwire.com.
More

西銳飛機（2507.HK）發佈2024年度中期業績

08/29/2024
截至2024年6月30日止中期業績亮點：- 收入達約4.75億美元，同比增長11.6%- 毛利達約1.63億美元，毛利率為34.4%- 利潤達約3,560萬美元，同比穩健增長23.6%- 於2024年上半年，公司於市場推出了屢獲殊榮的SR2X系列的第七代(G7)，該系列在過去連續22年一直為全球最暢銷的單引擎活塞模型飛機。- SR2X和願景噴氣機合計淨訂單量從截至2023年6月30日止六個月的255架增至截至2024年6月30日止六個月的362架，合計增加了107架。香港, 2024年8月29日 - (亞太商訊 via SeaPRwire.com) — 西銳飛機有限公司(「Cirrus Aircraft」或「公司」及其附屬公司(統稱「集團」，2507.HK)公佈，截至2024年6月30日止6個月(報告期間)之未經審核綜合業績。報告期間，集團收入由去年同期4.26億美元增長11.6%至4.75億美元，毛利由去年同期1.49億美元穩增10%至1.63億美元。期內利潤由去年同期2,880萬美元顯著提升23.6%至3,560萬美元，主要由於飛機交付量的增加、飛機定價的增加以及西銳服務及改善西銳服務及其他的收入組合以實現利潤率較高的服務。全球私人航空市場的領導者自1984年於美國威斯康星州成立以來，西銳飛機一直致力於設計、開發、製造及銷售私人航空業公認的優質飛機，在安全、技術、連接、性能及舒適度方面均有所創新。公司的兩條飛機產品線，即SR2X系列及願景噴氣機，已成功確立自駕飛機的行業標準，目前已在60多個國家獲得認證及驗證，並已累計交付逾9,700架SR2X系列飛機和逾550架願景噴氣機。作為廣泛的產品組合戰略的一部分，公司的SR2X系列包括入門級飛機SR20以及SR22和SR22T，後兩款飛機具備不斷提升的性能和能力，以滿足客戶對單引擎活塞飛機的不同需求及偏好。SR2X系列飛機通常最多可承載四名成年人和一名兒童。而願景噴氣機則針對私人航空業的不同及更高端市場，提供顯著增強的性能、能力和規格，價格也較高。同時，願景噴氣機可讓擁有人在無專職飛行員或飛行部門支持的情況下以噴氣速度飛行。願景噴氣機通常最多可承載五名成年人和兩名兒童。隨著G7 系列的推出、產品組合的持續更新，將為保持業務增長及為客戶提供優質體驗帶來更大的核心驅動力。今年上半年，與2023年同期相比，西銳飛機多交付了20架飛機，且平均銷售額穩中有升。其中，SR2X飛機交付的平均銷售額約為104萬美元，而2023年同期為99萬美元。願景噴氣機交付的平均銷售額為333萬美元，而2023年同期為308萬美元。與此同時，公司的SR2X和願景噴氣機合計淨訂單量從截至2023年6月30日止六個月的255架增至截至2024年6月30日止六個月的362架，合計顯著增加了107架。這一增長部分歸因於G7系列的推出，以及兩條產品線之間產品階梯的延續和圍繞擁有體驗不斷發展的生態系統。報告期內，公司錄得的強勁淨訂單量增長將為其穩定增長帶來良好的動力。展望及未來計劃未來，西銳飛機將持續專注改進產品，不斷推動機型升級及代際變革，為飛機配置新技術及新設計，以鞏固行業領先地位。與此同時，公司將通過一系列的措施，包括通過建立(其中包括但不限於)新的維護計劃及擴展飛機管理解決方案以及一系列行之有效的客戶服務，以實現已有客戶群的變現、改進飛行訓練解決方案、 推進並擴大飛機和服務組合、提高生產能力、拓展全球市場，以及打造按需私人航空解決方案，以支持未來業務增長及集團的長期穩定發展。最近，公司亦已完成了大福克斯生產設施的重大改進，包括擴大蒸壓及模具產能，以作為持續努力提高生產設施產能和效率的一部分。此外，公司亦持續增加生產設施的面積，並實施西銳操作系統(COS)，以持續提高其營運效率，並預計相關舉措可持續改進將有助於增加並支持未來生產。在市場營銷方面，公司將把其在英國和法國的銷售結構由西銳銷售代理調整為直接銷售，預期將透過在銷售週期早期與客戶建立直接關係、在客戶擁有產品的整個體驗中維繫更緊密的關係，從而策略性地直接推動銷售及營銷計劃，以推動公司在這些市場的成長。另外，公司將持續擴大對產品組合的投資。於2024年4月，公司的SR10飛機獲得了美國運輸部聯邦航空管理局的生產許可證，這是同類產品中第一款專門用於培訓下一代飛行員的全新設計。 - 完 -關於西銳飛機有限公司西銳飛機成立於1984年的美國威斯康星州，是一家從事設計、開發、製造及銷售私人航空業公認的優質飛機的公司，在安全、技術、連接、性能及舒適度方面均有所創新。根據弗若斯特沙利文的資料，按2023年已交付量計， 西銳飛機於全球私人航空市場的市場份額達32.0%。公司的兩條飛機產品線(即SR2X系列及願景噴氣機)已成功確立自駕飛機的行業標準，目前已在60多個國家獲得認證及驗證。根據通用航空製造商協會的資料，SR2X系列飛機於過去22年一直是最暢銷的單引擎活塞機型。自願景噴氣機於2016年首次交付以來，其可讓擁有人在無專職飛行員或飛行部門支持的情況下以噴氣速度飛行，根據通用航空製造商協會及弗若斯特沙利文的資料，願景噴氣機已連續六年成為最暢銷的公務機。截至2024年2月29日，西銳飛機的全球客戶群已擁有超過10,000架公司的飛機。此新聞稿由博達浩華國際財經傳訊集團代西銳飛機有限公司發佈。如有垂詢，請聯絡：博達浩華國際財經傳訊集團電話︰852 3150 6788 電郵︰cirrusaircraft.hk@h-advisors.global Copyright 2024 亞太商訊 via SeaPRwire.com.
More

Cirrus Aircraft (2507.HK) Announces 2024 Interim Results

08/29/2024
Results Highlights for the Six Months Ended June 30, 2024:- Revenue reached to approximately US$475.4 million, grew by 11.6% YoY- Gross Profit amounted to approximately US$163 million and gross profit margin was 34.4%- Profit grew significantly by 23.6% to approximately US$35.6 million- In the first half of 2024, the Company brought to market the 7th generation (G7) of the SR2X Series, which has been the best-selling single-engine piston model aircraft in the world for the last 22 consecutive years.- Net orders increased for both the SR2X and Vision Jet combined for the six months ended June 30, 2024 by a total of 107 units from 255 for the six months ending June 30, 2023 to 362 for the six months ending June 30, 2024.HONG KONG, Aug 29, 2024 - (ACN Newswire via SeaPRwire.com) - Cirrus Aircraft Limited (“Cirrus Aircraft” or “Company”) and its subsidiaries (together, the “Group”)( 2507.HK) announces the unaudited consolidated results for the six months ended June 30 2024 (the “Reporting Period”).During the Reporting Period, revenue of the Group grew by 11.6% to US$475.4 million, as compared with US$426.0 million for the same prior year period. Gross profit increased by 10.0% to US$163.4 million as compared with US$14.8 million for the same prior year period. Profit for the Reporting Period significantly increased by 23.6% from US$28.8 million for the same prior year period to US$35.6 million. It is primarily due to increased aircraft deliveries, increased pricing on the aircraft, and better mix of revenue generated from Cirrus Services and Other towards its services with higher margin.The leading aircraft manufacturer in the global personal aviation marketSince the inception in 1984 in Wisconsin, United States, Cirrus Aircraft is committed to design, develop, manufacture, and sell premium aircraft recognized across the personal aviation industry, which incorporate innovations in safety, technology, connectivity, performance, and comfort. The Company’s two aircraft product lines, the SR2X Series and the Vision Jet, have successfully set the industry standard for owner-piloted aircraft and are currently certified and validated in more than 60 countries with cumulative deliveries of over 9,700 SR2X Series aircraft and over 500 Vision Jet aircraft worldwide as of the June 30, 2024.As part of its wide-ranging product offering strategy, the Company’s SR2X Series consists of an entry level aircraft, the SR20, as well as the SR22 and SR22T, both of which offer increasing levels of performance and capabilities addressing different customer needs and preferences for a single-engine piston aircraft. SR2X Series aircraft can typically carry up to four adults and one child. The Vision Jet targets a different and more premium segment of the personal aviation market and offers significantly enhanced performance, capabilities and specifications at a higher price point. The Vision Jet is also designed for owners to fly at jet speed without requiring support from a full-time pilot or flight department. The Vision Jet can typically carry up to five adults and two children. With the launch of the G7 line and continuous upgrade of product portfolio, it will sustain the growth of the business and continue to provide a premium experience for the customers.In the first half of 2024, Cirrus Aircraft delivered 20 more aircraft and the average sales prices (“ASP”) of all deliveries steady increased as compared to the same period in 2023. The average sales price of the SR2X aircraft deliveries was approximately US$1.04 million compared to US$0.99 million in the same period in 2023. The average sales price of the Vision Jet aircraft deliveries was US$3.33 million compared to US$3.08 million in the same period in 2023. At the same time, net orders increased for both the SR2X and Vision Jet combined for the six months ended June 30, 2024 by a total of 107 units from 255 for the six months ending June 30, 2023 to 362 for the six months ending June 30, 2024. This increase is partly attributable to the launch of the G7 line as well as the continuation of the product ladder between the two product lines and the growing ecosystem around the ownership experience. The significantly increased net orders recorded during the Reporting Period will bring a great momentum for the steady growth of the Company.Outlook and Future PlanIn the future, Cirrus Aircraft will continue to focus on product improvement, model upgrades and ongoing generational changes to equip its aircraft with new technologies and designs to consolidate the leading position of the industry. Meanwhile, the Company intend to adopt a series of measures, including monetize installed base through establishing, among many things but not limited to, new maintenance programs, and expanding aircraft management solutions and an array of useful customer services, enhance flight training solutions, advance and expand its aircraft and services portfolio, advance production capabilities, expand its markets globally and establish on-demand personal aviation solutions, to support the future business development and the long-term steady growth of the Company.In recent, as part of the ongoing efforts to increase the capacity and efficiency of the manufacturing facilities, the Company has also completed significant improvements in its manufacturing facility in Grand Forks, including expanded autoclave and mold capacity. In addition, the Company continues to increase the areas of the production facilities in which the Company has implemented its Cirrus Operating System (COS) which continues to increase the operating efficiency. Cirrus Aircraft anticipates these continued improvements will help increase and support future production.In regards to the marketing strategy, the Company adjusted its sales structure in the United Kingdom and France from CSAs to direct sales, which the Company anticipates will drive growth in these markets by developing direct relationships with the customers earlier in the sales cycle, maintaining closer relationships throughout the customers’ ownership experience and allowing the Company to strategically and directly drive sales and marketing initiatives. Moreover, the Company continues to expand the investment within its product portfolio. In April 2024, the Company received the production certificate from Federal Aviation Administration of the U.S. Department of Transportation for its SR10 aircraft, which is the first of its kind clean sheet design exclusive to training the next generation of pilots. - End -About Cirrus Aircraft LimitedCirrus Aircraft Limited is a pioneer and an established global market leader in the personal aviation industry, according to Frost & Sullivan. The Company designs, develops, manufactures, and sells premium aircraft recognized across the personal aviation industry, which incorporate innovations in safety, technology, connectivity, performance, and comfort. The market share of Cirrus Aircraft in the global personal aviation market was 32.0% in 2023 based on the number of units delivered, according to Frost & Sullivan. The Company’s two aircraft product lines, namely SR2X Series and Vision Jet, have successfully set the industry standard for owner-piloted aircraft and are currently certified and validated in more than 60 countries. According to GAMA, SR2X Series has been the best-selling single-engine piston aircraft for 22 consecutive years, while according to GAMA and Frost & Sullivan, Vision Jet has been the best-selling business jet for the last six consecutive years since it first delivered in 2016.This press release is issued by Porda Havas International Finance Communications Group for and on behalf of Cirrus Aircraft Limited. For further information, please contact:Porda Havas International Finance Communications GroupTelephone: 852 3150 6788Email: cirrusaircraft.hk@h-advisors.global Copyright 2024 ACN Newswire via SeaPRwire.com.
More
技術革新引領綠色發展，國際化戰略加速推進 ACN Newswire

技術革新引領綠色發展，國際化戰略加速推進

08/29/2024
香港, 2024年8月29日 - (亞太商訊 via SeaPRwire.com) — 中國新能源電池行業領軍企業--天能動力國際有限公司(「公司」，連同其附屬公司，統稱「集團」或「天能」）（股份代號：00819.HK)公布截至2024年6月30日止六個月（「報告期內」）之中期業績。2024年上半年，天能動力著力構建新質生産力，以「實業、科技、資本」三輪驅動和「數智化、平臺化、國際化」三化聯動，構成新發展格局。集團堅持貫徹「科技創新是發展新質生産力的核心要素」的理念，進一步升級和優化鉛蓄電池的生産工藝，積極開拓鋰、氫、鈉、固態等新興電池的布局和應用。同時，致力于應對全球氣候變化挑戰，通過綠色智能製造、發展循環經濟提升效益和保護環境，打造可持續供應鏈，與國家高質量發展、現代化治理等一系列發展目標相契合。報告期內，集團取得營業收入約人民幣499.15億元，較去年同期增長約20.36%；公司擁有人應占溢利約人民幣9.28億元，較去年同期增長約1.09%。在積極探索新興業務發展的同時，天能投入大量精力鞏固和加强主業的龍頭地位，基石業務鉛蓄電池取得營業收入約人民幣192.52億元；在新能源電池領域，天能加快開拓鋰電儲能，加速迭代氫燃料電池及鈉離子電池，實現了關鍵技術的突破和多元場景的應用；在循環經濟領域，天能打造集生産、回收、冶煉、再生産為一體的電池循環綠色産業鏈，可循環産業取得對外營業收入約人民幣15.54億元。突破壁壘 持續技術革新集團已形成「動力電池、儲能系統」雙核發力格局，在傳統賽道實現「鉛鋰幷行」，在新興賽道加速開拓氫燃料電池、鈉離子電池、固態電池。在動力領域，天能先後推出了首款電動摩托車專用鉛蓄動力電池、新一代鈉離子動力電池「天鈉T2」、叉車用純膠體蓄電池等，適配更多元應用需求；在儲能領域，成功開發OPzV-1000閥控膠體鉛炭電池、適用儲能場景的「鈉儲1號」、新一代5MWh鋰離子電池智能液冷儲能系統等，助力系統發揮更大價值，為各種應用場景提供穩定可靠的電力支持。綠色産業 堅守可持續發展戰略天能作為全球最大的鉛蓄電池製造企業之一，90%以上的電池産品用于電動輕型車，在交通出行領域具有天然的低碳優勢。天能將綠色智能製造納入企業發展戰略，優化生産流程，提升自動化覆蓋率和生産效率；通過開發幷植入多個數字管理系統，提高生産管理的數字化水平。不斷推動企業向著更高效、更環保的未來邁進。專注電池産業的同時，天能也致力于實現更加高效的資源回收與再生利用。現已在全國建設有4大鉛蓄電池循環經濟産業園和2大鋰離子電池循環經濟産業園，廢舊鉛蓄電池中各材料回收率超過99%，廢舊鋰離子電池中的硫酸鹽回收率超過98.5%，碳酸鋰回收率達到90%。在鉛蓄電池回收領域，天能不斷提升回收端與處置端的能力，形成穩定的可持續供應鏈，提升産能利用率，現已具備100萬噸的廢舊鉛蓄電池年處置能力。在鋰電回收領域，天能現具備1萬噸廢舊三元鋰離子電池的年處置能力，新建6萬噸産能將于本年投産。天能不斷創新電池回收技術，現擁有帶電破碎智慧分選、拆解物定向熱解、三元磷酸鐵鋰共綫處置、冷凍提鋰等多種鋰離子電池循環技術儲備。報告期內，集團地處浙江省湖州市長興縣的循環經濟産業園承接的廢舊鉛蓄電池回收處理項目，成為浙江省首個「國家循環經濟標準化示範項目」。該項目通過將典型模式轉化為國家標準，引領了行業發展的方向。工信部公布2023年度綠色製造名單，集團主營鋰電回收的子公司天能新材料有限公司入選國家級「綠色工廠」。與時俱進 加强品牌推廣市場方面，集團已建立廣泛的分銷和售後服務網絡，在中國擁有超3,000家分銷及售後服務網點，覆蓋超過40萬家終端門店，為4億電動輕型車用戶提供替換和維修服務，是市場上最為人所熟知的電池品牌之一。天能積極擁抱大數據技術與新興互聯網市場，利用數字化手段賦能市場營銷，助力合作夥伴進行精細化運作和管理。報告期內，集團深化推進數字營銷模式和天能創新雲商模式升級，極大優化了集團的柔性生産，能够更快速、準確地響應市場需求變化，進行生産計劃的調整，顯著提高運營效率。建立了數十家綫上綫下融合服務體驗中心，促進了定製品銷售的增長，渠道增質效果顯著，競爭力進一步提升。奮勇前進 拓展國際化經營在持續鞏固中國行業領先地位的同時，天能也因地制宜，將電池産品和能源解决方案快速推向全球市場。天能海外業務布局遍布東南亞、歐洲、非洲等多個國家和地區：董事局主席張天任先生于2024年4月受邀參加了「中國－越南貿易投資合作促進論壇」，首個海外智能製造基地落地越南，成為拓展東南亞市場的橋頭堡；成功簽訂數十家天能品牌海外合作夥伴，展開海外終端分銷及售後服務網絡鋪設；高頻亮相首爾電動車及電池展（EV TREND KOREA）、德國慕尼黑電池儲能展覽會（EES Europe）等國際性展會，獲得來自世界各地客戶的認可。依托在綠色能源産品的技術創新成果和深耕多年的行業經驗，國際市場將成為天能未來發展的新舞臺。繼本地化辦事處建設、海外銷售渠道布局、越南建廠項目之後，天能將繼續開拓海外市場，積極響應國家「一帶一路」倡議，以東南亞市場為切入點，聯合更多志同道合的合作夥伴，提升海外市場的影響力，把握國際競爭中的主動權。展望未來天能將堅持「聚焦高質量、深耕可持續」的發展方向，加快打造具有天能特色的新質生産力。以技術創新為推手，以調整結構為主綫，重點推進新能源産業的轉型升級，全力培育動力電池和儲能系統兩大産業生態圈。同時，以電池全生命周期産業為基礎，發揮循環經濟的規模優勢，提升效益。利用自身技術優勢，充分發揮科技創新的支撑引領作用，為「雙碳」戰略貢獻更多清潔能源系統解决方案，為國家生態文明建設做出更多貢獻。 －完－此新聞稿由博達浩華國際財經傳訊集團代天能動力國際有限公司發布。如有垂詢，請聯絡：馮嘉莉電話：+852 3150 6788電郵：tianneng.hk@pordahavas.com Copyright 2024 亞太商訊 via SeaPRwire.com.
More
中集集團公佈2024年中期業績 ACN Newswire

中集集團公佈2024年中期業績

08/29/2024
財務摘要人民幣（億元，%）截至6月30日止6個月變動 變動2024年2023年24Q224Q1營業收入791.15605.7430.61%466.72324.4343.86%營業利潤21.1516.4528.60%17.084.07319.8%淨利潤13.959.940.85%11.772.18440.12%歸屬於母公司股東及其他權益持有者的淨利潤8.663.99117.23%7.820.84835.19%歸屬於母公司股東及其他權益持有者的扣非淨利潤8.209.77(16.00%)5.952.25164.48%業績亮點01. 集裝箱製造業務保持全球領先地位，業績顯著提升：受益於集運需求提升及紅海等不確定事件導致的運輸效率下降，標準乾箱銷量同比增長425.54%.上半年集裝箱製造業務營收同比提升83%至249.5億元，淨利潤同比上升66%至12.76億元02. 海工經營收入大幅增長：受益於海工裝備市場繼續恢復向好，板塊營業收入同比大幅增長89%至人民幣77.8億元，新簽訂單同比增長20.1%至17.9億美金，在手訂單同比增長20.9%至61.8億美元，其中油氣：風電：滾裝船訂單佔比約為2:1:1，淨虧損持續縮窄54%至0.84億；03. 道路運輸、能源化工液態食品兩大分部業務穩健經營：車輛業務實現收入107億元，實現淨利潤人民幣5.74億元，半掛車市場佔有率提升並保持國內第一；安瑞科營業收入同比增長6.7%至人民幣114.8億元，累計在手訂單至人民幣293.5億元，創歷史新高。香港, 2024年8月29日 - (亞太商訊 via SeaPRwire.com) — 中國國際海運集裝箱（集團）股份有限公司（簡稱「中集集團」或「集團」，股份代號：000039.SZ/02039.HK）欣然公佈截至2024年6月30日止6個月（「期內」）之未經審核中期業績。中集集團管理層表示：「2024年上半年，全球商品貿易需求回升，集裝箱市場企穩回暖、能源安全及消費需求增長、全球船舶和海工市場環境持續向好，集團基於不斷夯實的全球營運平台基礎，平抑了單一地區的風險波動，實現了穩健有質發展。上半年，集團實現營業收入791億，同比提升30.61%，毛利率保持在10.73%，歸母淨利潤約人民幣8.7億，同比大幅提升117%。期內，集團集裝箱產業持續保持全球行業領先地位，道路運輸車輛、能源/化工/液態食品裝備以及海工業務也形成了較強的全球競爭力。集團國內營業收入佔比約45.55%，國外營業收入佔比約54.45%，與去年同期相比基本持平，維持較好的市場格局。」主要板塊經營表現（人民幣億元）1H2024各項指標營業收入佔總營收比重毛利佔總毛利比重毛利率淨利潤集裝箱製造249.5031.54%30.4335.85%12.20%12.76道路運輸車輛107.0013.52%15.9518.80%14.91%5.74能源、化工液態食品裝備121.2115.32%16.0118.86%13.21%2.42海洋工程77.849.84%3.894.58%4.99%(0.84)空港與物流裝備、消防與救援設備24.033.04%4.945.82%20.54%0.37物流服務140.8917.81%8.7710.34%6.23%2.04循環載具11.971.51%1.441.21%12.05%(0.49)以上主要板塊732.4392.58%81.4295.94%11.12%22.00核心業務表現在物流領域集裝箱製造方面，期內全球商品貿易需求回升，紅海事件等不確定事件導致歐線繞航，降低了集運運輸效率，集裝箱需求有所提升。集團集裝箱製造業務產銷量同比明顯增長，其中乾貨集裝箱累計銷量138.27萬TEU（去年同期：26.31萬TEU），同比增長約425.54%；冷藏箱累計銷量4.47萬TEU（去年同期：5.15萬TEU），同比下降約13.2%。期內，集團集裝箱製造業務實現營業收入人民幣249.5億元（去年同期：人民幣136.68億元），同比上升82.54%，實現淨利潤人民幣12.76億元（去年同期：人民幣7.68億元），同比上升66.25%。期內，面對集運市場運輸需求激增及紅海事件繞道導致的集裝箱週轉效率降低的問題，集團迅速行動，成功實現生產效率與交付能力的顯著提升，同時提升了整體運營效率與市場競爭力。在類似驅動因素催化下，物流服務業務方面，集團上半年多數產品業務量及盈利能力同比均有較大幅度的增長，且二季度相比一季度增長明顯。期內，物流服務業務實現營業收入人民幣140.89億元（去年同期：人民幣91.32億元），同比上漲54.28%；淨利潤為人民幣2.04億元（去年同期：人民幣0.55億元），同比上漲274.74%。上半年在多措並舉，主動應變中，集團物流服務的海運業務表現出色，在《Transprot Topic》2024年全球海運榜中，中集世聯達位列TOP13，在中國企業中排名第三。道路運輸車輛方面，中集車輛積極鍛造新質生產力，持續深化「星鏈計劃」，在上半年行業築底的背景下，迎難而上、逆勢破局，半掛車市場佔有率提升並保持國內第一。專用車方面，中集車輛繼續鞏固國內市場、開拓海外市場，同時積極研發一體化新能源產品，行業首創的頭掛一體化油電混動半掛牽引攪拌車開始小批量交付。期內中集車輛實現收入人民幣107 億元（去年同期：人民幣134.70億元），同比下降20.56%；淨利潤實現人民幣5.74億元。空港與物流裝備、消防與救援設備方面，中集天達通過整合海內外各地的生產和營銷佈局，積極推動一體化營運，從而降低整體經營成本，競爭激烈環境下仍維持自身優勢，盈利水平長期穩定增長，期內營業收入同比上升5.31%至24.03億元，淨利潤大幅提升364.81%至0.37億元。2024年上半年，旅客登機橋和消防車的驗收交付量增加，帶動空港與物流裝備、消防與救援設備兩線業務的營業收入均較去年同期上升，板塊整體利潤同比亦有增長。新簽訂單方面，空港市場需求持續恢復，國內「萬億國債」項目推動消防需求提升，整體新簽訂單保持增長。在能源領域海洋工程方面，上半年國際油價處於高位水平，促進了油氣生產平台需求的提升，持續增長的海洋作業活動推動海工裝備利用率和租金連續走高，海工裝備市場繼續恢復向好。期內，隨著海工新接訂單陸續進入建造期，集團海洋工程業務的營業收入為人民幣77.84億元（去年同期：人民幣41.19億元），同比增長88.95%。新簽訂單方面，截至6月底已生效/中標訂單同比增長20.1%至17.9億美元（去年同期：14.9億美元），包括2條FPSO船體、3條滾裝船；累計持有在手訂單價值同比增長20.9%至61.8億美元（去年同期：51.1億美元），其中油氣：風電：滾裝船訂單佔比約為2:1:1，有效平抑油氣市場的週期性波動，成功實現了戰略轉型。海工資產運營方面，集團上租平台延續高質量服務水平和上租率。在全球能源安全及消費需求背景下，海工市場保持活躍。深水平台市場受益於國際油公司持續投資開發推動，根據Rystad的預測，全球深水油氣鑽探的資本支出將同比增長10%，躍升至10多年來的最高水平金額，全球需求的提升及鑽井平台可用性的降低共同推動日費水平和利用率延續增長趨勢。期內，集團1座自升式鑽井平台Caspian Driller獲得客戶3+2年續約合同；1座中深水半潛式鑽井平台Deepsea Yantai獲得客戶續約合同，新租約較當前合同日費率提升超10%。能源、化工及液態食品裝備業務方面，期內實現營業收入人民幣121.21億元（去年同期：人民幣113.88億元），同比上升6.43%；淨利潤人民幣2.42億元（去年同期：人民幣4.35億元），同比下降44.52%。其中，安瑞科實現營業收入人民幣114.8億元（去年同期：人民幣107.6億元），同比增長6.7%，新簽訂單人民幣164億元（去年同期：人民幣126.7億元），同比增長29.5%，截至6月底在手訂單人民幣293.5億元（去年同期：人民幣206.0億元），同比大幅增長42.5%，創歷史新高。具體來看，清潔能源分部收入穩步增長，其中LNG儲運裝備、LNG車用瓶等終端運用裝備需求大幅增長，中小型液化氣船市場維持高景氣度，在氫能領域上期內成功收購北京眾聯盛核心資產，中標國內最大氨氫醇儲罐工程項目；化工環境分部罐式集裝箱全球市場份額蟬聯第一，保持發展韌性；液態食品分布緊抓國內烈酒市場成長機遇，中標多項烈酒項目。前景及未來計劃在物流領域集裝箱製造方面，根據克拉克森7月的預測，全球集裝箱貿易增速將從2023年的0.7%大幅提升至2024年的5.1%，並預計2025年集運貿易增速將繼續增長2.9%，集運市場運輸需求展望樂觀穩定。為應對不確定性事件帶來的缺箱風險，客戶備箱意願增強，疊加穩定的舊箱淘汰置換量，預計2024-2025年集裝箱新箱需求將有穩定的基本面支撐。道路運輸車輛方面，2024年下半年，中國物流運輸的需求逐步復蘇，中國半掛車行業加速轉型升級，邁向合規化、標準化、智能化、電動化的新發展階段。隨著美國降息政策確定性逐步增強，北美半掛車需求或將被釋放；隨著歐洲半掛車行業可持續發展監管趨嚴和多式聯運需求增長，需求放緩的歐洲半掛車行業或將受益。專用車行業存在預期復蘇，新能源專用車滲透率逐步提升，專用車運輸合規化進程加快推進。在能源領域能源、化工及液態食品裝備方面，高盛預測到2029年，全球對LNG的投資預計將增長50%以上，到2030年全球LNG供應量將激增80%。國內市場方面，IEA預測到2030年，中國在LNG有效合約中的份額將從2021年的12%翻番至25%左右。中集安瑞科作為清潔能源裝備先進智造龍頭企業，在LNG需求增長的驅動下，相關儲運裝備和工程業務有望持續受益，也將持續拓展東南亞、非洲、中東等海外市場的業務機會，將積極關注市場變化和機遇，深化「制儲運加用」全產業鏈佈局及一體化解決方案能力。此外，憑借多年在罐箱製造領域的生產技術和品質管理經驗，醫療設備部件業務的市場佔有率，並積極關注全球液態食品市場變化，持續關注國內烈酒等新賽道發展機遇。海洋工程方面，全較高的油價水平對油氣生產平台仍存在促進作用，海工建造市場進入上行週期的趨勢非常明顯，FPSO/FLNG市場的短期需求確定性高，長期項目儲備充足，預計未來海工製造商3-5年產能利用率將持續維持高位，中國海工企業憑借產業集群效應優勢正逐步與日韓海工企業競爭高技術門檻訂單。下半年，本集團海洋工程業務將繼續積極推進業務轉型，整合產業圖譜，以海洋油氣為基本面，逐步向新能源拓展，形成平抑週期的組合。在金融及資產管理領域中集海工資產運營管理業務方面，中集海工資產運營管理業務將繼續把握住海工市場的活躍週期，充分利用全產業鏈優勢推進市場開發，提高資產上租率，在合適的價格處置資產、回籠資金；以客戶需求為導向，提高客戶滿意度和拓展未來合作機遇；以精益管理持續強化成本管控力和核心競爭力，推動盈利能力穩健增長。集團管理層總結說：「上半年，集團通過鞏固提升已有核心業務的行業龍頭地位，並重點通過拓展多個戰略新興業務，核心業務實現了穩健優質增長，卓有成效的全球化業務佈局也有效地抵御了近年來全球市場週期波動的影響。展望下半年，集團將立足新發展階段，繼續緊跟國家戰略導向，深化落實「加快構建增長新動能，著力推動高質量發展」戰略主題，緊握新質生產力、「一帶一路」、統一大市場、科技創新、綠色發展等重要機遇，通過鞏固提升已有核心業務的行業龍頭地位，持續激活業務新價值和新動能，實現高質量增長目標。」-完-關於中國國際海運集裝箱（集團）股份有限公司中集集團是全球領先的物流及能源行業設備及解決方案供貨商，產業集群主要涵蓋物流領域及能源行業領域，龍頭市場地位持續鞏固。在物流領域，本集團仍然堅持以集裝箱製造業務為核心，孵化出道路運輸車輛業務、空港與物流裝備/消防與救援設備業務，輔之以物流服務業務及循環載具業務提供物流專業領域的產品及服務；在能源行業領域，本集團主要從能源/化工/液態食品裝備業務、海洋工程業務方面開展；同時，本集團也在不斷開發新興產業並擁有服務本集團自身的金融及資產管理業務。作為一家為全球市場服務的多元化跨國產業集團，中集在亞洲、北美、歐洲、澳洲等地區擁有300余家成員企業，集團旗下擁有3家上市公司，客戶和銷售網絡分布在全球100多個國家和地區。2023年，本集團業績實現營業收入人民幣1,278.10億元，毛利率保持在13.77%，淨利潤為人民幣18.63億元。2023年，本集團位列2023《財富》中國500強榜單第170名。如欲獲得更多信息，請瀏覽https://www.cimc.com/。 Copyright 2024 亞太商訊 via SeaPRwire.com.
More